 
Effect of Perimenstrual Ovarian Steroid 
Supplementation on Perimenstrual 
Suicidality  
 
(NIMH Grant Name: “Ovarian Hormone Withdrawal and Suicide 
Risk: An Experimental Approach”; K99MH109667; UNC IRB 
number 16-2078) 
 
 
 
NCT number  
Document Date 10-02-[ADDRESS_1259630] of Perimenstrual Ovarian Steroid 
Supplementation on Perimenstrual Suicidality  
(NIH Grant Name: [CONTACT_898868]: An Experimental Approach) 
 
Protocol Identifying Number: IRB # 16-2078  
Principal Investigator:  [INVESTIGATOR_202589]-Moul, Ph.D. 
IND/IDE Sponsor: Not applicable 
Funded by: [CONTACT_52042] (K99MH109667) 
Date: [ADDRESS_1259631] OF ABBREVIATIONS ..............................................................................................  i 
STATEMENT OF COMPLIANCE .....................................................................................  i 
PROTOCOL SUMMARY ..................................................................................................  i 
SCHEMATIC OF STUDY DESIGN ................................................................................. iv 
1 KEY ROLES ..........................................................................................................  6 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE ....................................................................................................................  7 
2.1 Background Information .................................................................................  7 
2.2 Rationale ........................................................................................................  7 
2.3 Potential Risks and Benefits ........................................................................  10 
2.3.1  Known Potential Risks ..................................................................  10 
2.3.2  Known Potential Benefits ..............................................................  12 
3 OBJECTIVES AND PURPOSE ...........................................................................  12 
4 STUDY DESIGN AND ENDPOINTS ....................................................................  12 
4.1 Description of the Study Design ...................................................................  12 
4.2.1  Primary Endpoint ...........................................................................  15 
4.2.2  Secondary Endpoints ....................................................................  15 
4.2.3  Exploratory Endpoints ...................................................................  15 
5 STUDY ENROLLMENT AND WITHDRAWAL .....................................................  15 
5.1 Participant Inclusion Criteria ........................................................................  15 
5.2 Participant Exclusion Criteria .......................................................................  23 
5.3 Strategies for Recruitment and Retention ....................................................  24 
5.4 Participant Withdrawal or termination ..........................................................  26 
5.4.1  Reasons for Withdrawal or Termination ........................................  26 
5.4.2  Handling of Participant Withdrawals or termination .......................  27 
5.5 Premature Termination or Suspension of Study ..........................................  27 
6 STUDY AGENT ...................................................................................................  28 
6.1 Study Agent(s) and Control Description .......................................................  [ADDRESS_1259632] Storage and Stability ........................................................  28 
6.1.4  Preparation ...................................................................................  28 
6.1.5  Dosing and Administration ............................................................  28 
6.1.6  Route of Administration ................................................................ . 28 
6.1.7  Starting Dose and Dose Escalation Schedule ...............................  28 
6.1.8  Dose Adjustments/Modifications/Delays .......................................  29 
6.1.9  Duration of Therapy ......................................................................  29 
6.1.10  Tracking of Dose ...........................................................................  29 
6.1.11  Device Specific Considerations .....................................................  29 
6.2 Study agent Accountability Procedures .......................................................  29 
7 STUDY PROCEDURES AND SCHEDULE .........................................................  29 
7.1 Study Procedures/Evaluations .....................................................................  [ADDRESS_1259633] of care study procedures ...............................................  31 
7.2 Laboratory Procedures/Evaluations .............................................................  31 
iii 
 7.2.1  Clinical Laboratory Evaluations .....................................................  31 
7.2.2  Other Assays or Procedures ...........  Error! Bookmark not defined.  
7.2.3  Specimen Preparation, Handling, and Storage .............................  31 
7.2.4  Specimen Shipment ......................................................................  32 
7.3 Study Schedule ............................................................................................  32 
7.3.1  Screening ......................................................................................  32 
7.3.2  Enrollment/Baseline ......................................................................  32 
7.3.3  Follow- up ......................................................................................  32 
7.3.4  Final Study Visit ............................................................................  34 
7.3.5  Early Termination Visit ..................................................................  34 
7.3.7  Schedule of Events Table .............................................................  34 
7.4 Justification for Sensitive Procedures ..........................................................  35 
7.5 Concomitant Medications, Treatments, and Procedures .............................  36 
7.5.1  Precautionary Medications, Treatments, and Procedures .............  36 
7.6 Prohibited Medications, Treatments, and Procedures ................................ . 36 
7.7 Prophylactic Medications, Treatments, and Procedures ..............................  36 
7.8 Rescue Medications, Treatments, and Procedures .....................................  36 
7.9 Participant Access to Study Agent At Study Closure ...................................  36 
8 ASSESSMENT OF SAFETY ...............................................................................  36 
8.1 Specification of Safety Parameters ..............................................................  37 
8.1.1  Definition of Adverse Events (AE) .................................................  37 
8.1.2  Definition of Serious Adverse Events (SAE) ................................ . 37 
8.1.3  Definition of Unanticipated Problems (UP) ....................................  [ADDRESS_1259634] .............................................................  41 
8.4.5  Reporting of Pregnancy ................................................................  41 
8.5 Study Halting Rules .....................................................................................  41 
8.6 Safety Oversight ..........................................................................................  42 
9 CLINICAL MONI TORING .....................................................................................  42 
10 STATISTICAL CONSIDERATIONS .....................................................................  43 
10.1  Statistical and Analytical Plans ....................................................................  43 
10.2  Statistical Hypotheses ..................................................................................  43 
10.3  Analysis Datasets ........................................................................................  43 
10.4  Description of Statistical Methods ................................................................  43 
10.4.1  General Approach .........................................................................  43 
10.4.2  Analysis of the Primary Efficacy Endpoint(s) ................................ . 44 
10.4.3  Analysis of the Secondary Endpoint(s) .........................................  44 
10.4.4  Safety Analyses ............................................................................  44 
iv 
 10.4.5  Adherence and Retention Analyses ..............................................  46 
10.4.6  Baseline Descriptive Statistics ......................................................  46 
10.4.7  Planned Interim Analyses .............................................................  46 
10.4.9  Multiple Comparison/Multiplicity ....................................................  47 
10.4.10  Tabulation of Individual Response Data ........................................  47 
10.4.11  Exploratory Analyses ....................................................................  47 
10.5  Sample Size ................................................................................................ . 47 
10.6  Measures to Minimize Bias ..........................................................................  48 
10.6.1  Enrollment/ Randomization/ Masking Procedures .........................  48 
10.6.2  Evaluation of Success of Blinding .................................................  48 
10.6.3  Breaking the Study Blind/Participant Code ...................................  48 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS .... 48 
12 QUALITY ASSURANCE AND QUALITY CONTROL ...........................................  48 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS ................................................  [ADDRESS_1259635] ...........................................................................  49 
13.3  Informed Consent Process ..........................................................................  49 
13.3.1  Consent/assent and Other Informational Documents Provided to 
Participants [ADDRESS_1259636] POLICY ....................................................................  53 
17  LITERATURE REFERENCES .............................................................................  53 
APPENDIX ....................................................................................................................  70 
 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259637] Randomized controlled trial 
SITBI Self-Injurious Thoughts and Behaviors Interview 
UWRAP/LRAP University of Washington Risk Assessment and Management 
Protocol/Linehan Risk Assessment and Management Protocol 
EXP Experimental 
PL Placebo 
EMA Ecological Momentary Assessment 
CESD  Center for Epi[INVESTIGATOR_898757]-Trait Anxiety Inventory 
UPPS -P An Impulsivity Scale measuring Urgency , lack of Premeditation , lack of 
Perseverance , Sensation seeking , and Positive Urgency. 
SSES  State Self-Esteem Scale 
FT-IRAP Future-Thinking Implicit Relational Assessment Procedure (Hopelessness 
Task) 
SAR-IAT Social Acceptance and Rejection Implicit Association Test (Negative Social 
Appraisals Task) 
SST Stop-Signal Task (Inhibitory Control Task) 
DPT Dot Probe Task (Threat Sensitivity Task) 
SCID Structured Clinical Interview for Diagnosis 
IDS Investigational Drug Services 
 
STATEMENT OF COMPLIA NCE  
 
The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on 
the Protection of Human Subjects (45 CFR Part 46), and the NIMH Terms o f Award. The 
Principal Investigator [INVESTIGATOR_7433], or changes to the  protocol will take 
place without prior agreement from the sponsor and documented approval from the In stitutional 
Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial 
participants. All personnel involved in the conduct of this study have completed Human Subjects 
Protection Training.  
 
PROTOCOL SUMMARY 
Title: Ovarian Hormone Withdrawal and Suicide Risk : An Experimental 
Approach 
Précis: 45 female outpatients with suicidal ideation but minimal1,2 imminent 
risk for attempt will complete behavioral tasks measuring 
hopelessness , social appraisals,  inhibitory control , and threat 
sensitivity as well as clinical interviews measuring suicidality in each 
of two conditions (order randomized across two menstrual cycle 
phases): (1) natural perimenstrual E 2/P4 withdrawal (placebo) , 
and (2) exogenous  stabilization of physiologic premenstrual 
(luteal phase ) E2/P4 to prevent withdrawal . Analyses will compare 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 ii 
 symptoms and suicidality under  placebo to symptoms and suicidality 
under  exogenous stabilization of E2 and  P4.  
Objectives: 
 The central aim of this mechanistic study is to experimentally 
test a pathophysiologic mediational model  in which E2/P4 
withdrawal increases perimenstrual suicidal desire (via increased 
hopelessness and negative social appraisals) and suicidal action 
capacity (via reduced inhibitory control and increased threat 
sensitivity). We predict that natural perimenstrual E2/P4 withdrawal 
(compared to stabilization) will be associated with greater 
perimenstrual suicidal desire (partially mediated by [CONTACT_898807]) 
and action capacity (partially mediated by [CONTACT_898808]). 
  
  
Endpoint Primary :  
 
(1) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of SITB Suicidal Ideation 
subscale score (operationalization of suicidal desire)  
 
(2) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of SITB Suicidal Planning 
subscale score (operationalization of suicidal action capacity ) 
 
Secondary: 
 
(1) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of BHI Hopelessness Score  
 
(2) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of CES-D Depression Total 
Score  
 
(3) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of UPPS-P Lack of 
Premeditation Impulsivity subscale  
 
(4) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of PROMIS Anxiety Total 
Score  
 
(5) Mean Within-Person Condition Difference (7 final placebo 
days – 7 final stabilization days) of SSES Social Evaluation/ 
Rejection Sensitivity subscale  
 
Population: 45 female outpatients with suicidal ideation but minimal1,2 imminent 
risk for attempt 
Phase: N/A – Mechanistic Experiment 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 iii 
 Number of Sites 
enrolling 
participants: 1 
Description of Study 
Agent : Transdermal Estradiol .1 mg/24hr weekly for two weeks , and Oral 
Micronized Progesterone 200mg (100mg each morning, 100mg 
each evening ) for two weeks 
Study Duration: 20 months 
Participant Duration: ~3 menstrual cycles (1 menstrual cycle lasts , on average , ~28 days) . 
Therefore, average participation will last roughly 3.5 months. 
 
  
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259638]:  
Administer Condition 1 Intervention (Placebo or Experimental).  
Complete Interview Assessment of suicidiality (SITBI). 
Complete Computerized Tasks Measuring Inhibitory Control, Hopelessness, Rejection  
Sensitivity, and  Threat Sensitivity. Assess side effects.  
Final Visit to Evaluate Suicide Risk 
and Facilitate Appropriate 
Referrals as Needed  Randomized Subject to a Condition Order  
Condition Order 2 : Experimental during visits 1-3,  
Placebo during visits 4 -6 (n= 15) Condition Order 1 : Placebo during visits 1 -3,  
Experimental during visits 4-6 (n= 15) 
Days 7, 14, and [ADDRESS_1259639]:  
Administer Condition 2 Intervention (Placebo or Experimental).  
Complete Interview Assessment of suicidiality (SITBI). 
Complete Computerized Tasks Measuring Inhibitory Control, Hopelessness, Rejection  
Sensitivity, and  Threat Sensitivity. Assess side effects.  
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 5 
  
Design Figure . Overview of the Two Within-Person Crossover Study Conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 6 
  
 
1 KEY ROLES 
 
Mark Chavez, Ph.D . – NIMH Program Officer , Email: [EMAIL_17149]. gov; Phone : (301) 443- 8942  
 
Tory Eisenlohr-Moul , Ph.D. – Primary Investigator , Clinical Psychologist, Clinician Responsible for Suicide 
Risk Assessment and Management ; University of North Carolina at Chapel Hill, [ADDRESS_1259640], 
Chapel Hill, NC [ZIP_CODE]. Email : [EMAIL_17150] ; [EMAIL_17151]. edu.  Phone: 859- 317-0503.  
 
Susan Girdler , Ph.D. – Primary Mentor  to the PI, Experimental Psychologist ; University of North Carolina at 
Chapel Hill; [ADDRESS_1259641], Chapel Hill, NC [ZIP_CODE]. Email : s_girdler@med. unc.edu.  Phone : 
[PHONE_18656] .  
 
Mitch Prinstein , Ph.D. – Supervising Clinical Psychologist Regarding Suicide Risk Assessment ; 
University of North Carolina at Chapel Hill, 240 Davie Hall , Chapel Hill, NC [ZIP_CODE]. Email : 
mitch.prinstein@unc. edu.  Phone : [PHONE_18657] .  
 
David Rubinow , M.D. (Primary Medical Expert)  – Medical Monitor , Supervising Physician Psychiatrist 
Regarding Hormone Administration ; University of North Carolina at Chapel Hill, Campus Box 7160, Chapel 
Hill, NC [ZIP_CODE]. Email: david_rubinow@med. unc.edu. 
 
Steve Young , M.D./Ph.D. – Consulting Physician Gynecologist, Consultant to [CONTACT_187951] ; University of 
North Carolina at Chapel Hill, Chapel Hill, NC [ZIP_CODE]. Email: steven_young@med. unc.edu. Phone : (919) 966-
5288.   
 
Joe Hodges, Medical Technician  – University of North Carolina at Chapel Hill, [ADDRESS_1259642], Chapel Hill, NC [ZIP_CODE] . Email: [EMAIL_17152]. Phone: (919) 972- [ADDRESS_1259643] Manager – University of North Carolina at Chapel Hill, [ADDRESS_1259644], Chapel Hill, NC [ZIP_CODE] . Email: [EMAIL_17153]. Phone: (919) 972- 7496 .  
 
Cheryl Walker, Endocrine Assay Lab Director – University of North Carolina at Chapel Hill, Department of 
Psychiatry Endocrine Assay Lab Director, Chapel Hill, NC, [ZIP_CODE]. Email: Cheryl_w [EMAIL_17154]. 
Phone: (919) 632- 1427 .  
 
Kai Xia, Ph.D., Study Biostatistician – University of North Carolina at Chapel Hill, Department of 
Biostatistics, Chapel Hill, NC, [ZIP_CODE]. Email: [EMAIL_17155] . Phone : (919) 843- 5508 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 7 
  
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFI C RATIONAL E  
 
2.[ADDRESS_1259645] when  a woman will attempt suicide. Suicide accounts for 13% of all deaths among reproductive-age 
American females69. Although existing models of suicide risk provide information about long-term, stable risk 
stemming from factors such as depression, interpersonal sensitivity, anxiety, or impulsivity, little is known about  
when these or other factors will translate into acute risk for a suicide attempt5,6,70. By [CONTACT_898809]3 and focusing on biologic triggers and cognitive/behavioral mediators of acute changes in 
suicide risk, the present research responds to public calls from the U.S. President, Congress, Surgeon General, 
and the NIMH-co-sponsored Suicide Research Prioritization Agenda5, to identify strong predictors of acute 
suicide risk6. Such work is imperative in developi[INVESTIGATOR_898758], 
and will improve the precision and effectiveness of critical efforts to block suicide attempts.  
 
Perimenstrual (around menses) withdrawal from estradiol (E2) and progesterone (P4) may represe nt a 
time-varying biological mechanism of acute suicide risk. The perimenstrual period, which is characterized 
by [CONTACT_898810] E2 and P4, is associated with more hospi[INVESTIGATOR_898759]54-56,71, more lethal 
attempts55, and suicide deaths57. Despi[INVESTIGATOR_140867], no research has examined a causal role of 
perimenstrual ovarian steroid withdrawal in suicidality.  The rationale for studying hormone withdrawal  as a 
predictor of suicidality comes from work showing that withdrawal from  normal  levels  of E2/P4, rather than differing  
absolute  levels, precipi[INVESTIGATOR_898760]39,72.  
 
The experiment  will test a model in which perimenstrual E2/P4 withdrawal (vs. experimental luteal 
stabilization via transdermal E2 and oral micronized P4; STUDY AGENT) inc reases acute risk for 
suicidality  by [CONTACT_898811] (hopelessness, social  appraisals, 
inhibitory control, threat sensitivity) and parallel clinical symptoms (depres sion, impulsivity, rejection sensitivity, 
anxiety). To maximize both safety and generalizability, we will study women with suicidal ideation but minimal1,[ADDRESS_1259646] likely73,74 to influence suicide risk is informed by [CONTACT_898812]61,75, which posits that suicidal behavior arises from two acute risk factors: Suicidal Desire —a wish to 
die, and Suicidal Action Capacity —a readiness to act  on urges. Suicidal desire  is strongly predicted by 
[CONTACT_898813] (thwarted belongingness, perceived burdensomeness)61,76. 
Suicidal action capacity  is predicted by [CONTACT_898814]77 and threat sensitivity —a tendency toward 
detection and reactions to threats (fostered by [CONTACT_898815])63,77. Because this is an integrative 
theory, the constructs measured here will allow testing of a variety of theories  (e.g., Neurocognitive Theory60).  
 
Ovarian Steroid Changes Robustly Modulate Key Mediators of Suicidal Desire and  Action Capacity 
 
1. Hopelessness repeatedly emerges as the most robust  prospective predictor of suicidal desire in 
inpatients78 and outpatients59. Furthermore, hopelessness58 and suicide60,62,79 share functional alterations of 
the dorsomedial prefrontal cortex, supporting a central role of hopelessness in suicida lity. 
Ovarian steroid withdrawal may increase hopelessness (and associated symptoms of depression) . In 
animals, ovarian steroid withdrawal increases depressive behavior via GABAergic75 and serotonergic76,[ADDRESS_1259647] suicidal desire . Relationships are central to our ability to survive and 
thrive80. Perceptions of social rejection are experienced as painful81,82 and increase suicidal desire61—
particularly in reproductive-age women83,84. Additionally, suicidality is associated with altered function of brain 
regions associated with experiences of social exclusion  and rejection60.  
Ovarian steroid withdrawal may increase negative social appraisals (and associated symptoms of rejection 
sensitivity) . In animals, E2 and P4 facilitate social motivation and behavior85-87, and ovarian steroid withdrawal 
precipi[INVESTIGATOR_898761]67. In women, elevated luteal P4 correlates with social motivation88  and attention 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 8 
 to social-affiliative opportunities89. The PI’s longitudinal work indicates that ovarian steroid withdrawal predicts 
increased  daily appraisals of social rejection in women at elevated suicide risk8,40.  
3. Poor inhibitory control  enables suicidal desire to escalate into suicidal action63,90. Suicidal ideation alone 
is a poor predictor of suicidal behavior6; however, the addition of poor inhibitory control robustly predicts 
suicide attempts, suggesting its relevance for suicidal action capacity64,91,92. Suicide attempters and victims 
show deficiencies in the functioning of inhibitory circuits63,93- 97.  
Ovarian steroid withdrawal may reduce inhibitory control (and increase associated symptoms of 
impulsivity ). Cyclical E2/P4 withdrawal predicts poorer inhibitory control, greater impulsivity,8,98-100  and 
decreased frontal cortex inhibitory activity101, while high, stable ovarian steroids increase frontal cortex inhibitory 
activation102,103. Cyclical reductions in inhibition are particularly marked in women with low prefr ontal dopamine, 
which corresponds to the greater impulsivity found in suicide victims60,104. In animals, baseline impulsive behavior 
is a risk factor for greater sensitivity to ovarian steroid withdrawal105,106.  
4. Threat sensitivity, (defined as increased attention  and reflexive  responses  to threats), predicts suicidal 
behavior63,84,107. Repeated engagement of physiological stress systems also leads to HPA axis 
dysregulation, which prospectively predicts suicide attempts  among chronically suicidal individuals108. Other 
research in suicide victims indicate that generalized  threat sensitivity and reactivity to stimuli in daily life are 
acutely elevated prior to fatal suicidal behavior107. 
Ovarian steroid withdrawal may increase threat sensitivity (and associated symptoms of anxiety) . In 
animals, E2/P4 withdrawal increases threat sensitivity and reactivity65 and causes threat-sensitizing alterations 
in associated brain circuitry, including the amygdala109-111, the bed nucleus of the stria terminalis111,112, and the 
periaqueductal grey113,114, mediated by [CONTACT_898816] A receptor subunits that elicit anxiogenic 
effects of P4-derived neurosteroids109,115-121. In women, c orrelates of suicidality  including social stress122, social 
isolation123, lifetime abuse40, impulsivity105, and PTSD 124,125, predict greater effects of ovarian steroid withdrawal 
on threat sensitivity. Cyclical reductions in E2/P4 correlate with morphological an d functional changes in CNS 
fear and anxiety circuitry, especially amygdala sensitivity73,126,127.  
 
Despi[INVESTIGATOR_898762] E2/P4 withdrawal negatively modulates key 
mediators of suicide risk as outlined above,  the present research will be the first to experimentally confirm 
(or refute) a pathophysiologic role for steroid hormone withdrawal on suici de risk factors in humans, 
generally, and in at risk  women , specifically . The study delineates the within-person effects of ovarian steroid 
withdrawal on suicidal desire (via mediators hopelessness and social appraisals), and suici dal action capacity 
(via mediators inhibitory control and threat sensitivity). 
 
 
 
2.2 RATIONALE  
 
The objective of this experiment is to 
experimentally determine the pathophysiological 
role of perimenstrual ovarian steroid hormone 
withdrawal on acute suicide risk.   Suicidal 
behavior arises from two proximal risk factors:  
Suicidal desire, defined as the wish to die,  and 
suicidal action capacity, defined as a readiness to 
act on suicidal urges.  Hopelessness58-[ADDRESS_1259648] 
suicidal desire.  Poor inhibitory control60,63 and 
threat sensitivity60,63,64 (cognitive bias to interpret 
stimuli in a threat-related manner) are constructs 
reflecting dysregulation in central cognitive control 
and threat avoidance networks, and, in turn, are 
strong predictors of suicidal action capacity (right 
side of Figure at right ).  
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 9 
  
The RATIONALE for examining ovarian steroid withdrawal in suicide risk stems from evidence that 
withdrawal from estradiol (E2) and progesterone (P4), such as that occurr ing naturally during the perimenstrual 
timeframe,  modulate each of the mediating constructs and associated clinical symptom s8 (Figure above) toward 
risk, exerting robust anxiogenic, depressogenic, and impulsogenic effects in animals65-67 and increasing 
depression, anxiety, rejection sensitivity, and impulsivity in susceptible women (prelimina ry work by [CONTACT_976])8,40. 
However, no experimental work has directly evaluated whether perimenstrual E2/P4 withdrawal 
influences suicidality.  The experiment will determine the effects of perimenstrual E2/P4 wi thdrawal on suicidal 
desire and action capacity in at-risk women, testing mediation by [CONTACT_66443]-related behav ioral constructs.  
 
Design Overview:  30 female outpatients with suicidal ideation but minimal1,2 imminent risk for attempt will 
complete behavioral tasks measuring hopelessness, social appraisals,  inhibitory control, and threat sensitivity 
as well as clinical interviews in each of two conditions (order randomized across t wo menstrual cycle phases): 
(1) natural perimenstrual E2/P4 withdrawal (placebo) , and (2) exogenous stabilization of physiologic 
premenstrual (luteal phase) E2/P4 to prevent withdrawal . Daily calls will also assess symptoms and 
suicidality.   
 
 
CENTRAL HYPOTHESIS: Experimentally test a pathophysiologic mediati onal model  in which late luteal 
(perimenstrual) E2/P4 withdrawal (vs. experimental luteal E2/P4 stab ilization) increases suicidal desire (via 
increased hopelessness and negative social appraisals) and suicidal action capacity (via reduced inhibitory 
control and increased threat sensitivity). We predict that natural E2/P4 withdrawal (compared to stabilization) will 
increase reports of suicidal desire (partially mediated by [CONTACT_898817]) and action capacity (partially mediated by [CONTACT_898818]). 
 
JUSTIFICATION OF E2/P4 DOSING AND SCHEDULE 
 
In collaboration with Drs. Girdler, Young, and Rubinow, the PI [INVESTIGATOR_898763] E2 and P4 and will mimic luteal phase concentrations or E2 and P4. 
 
General Rationale for Route and Dose of E2 and P4.  We will use Climara® 7 day transdermal E2 patches. 
Peak levels of E2 with Climara (~45 pg/mL), achieved within [ADDRESS_1259649] a high affinity for androgen and mineralocorticoid receptors, limiting their usefulness for testing our 
hypotheses. Thus, oral prometrium will be dosed b.i.d. to achieve luteal P4 levels4 to create more steady-state 
levels  and minimize the variability that can occur with the oral route.  
 
Rationale for Timing and Duration  of E2/P4 . Administration for [ADDRESS_1259650] rual cycle.  
 
Compliance checks:  Participants will: 1) be educated on the importance of replacing their patches every 7 
days, with individualized strategies to enhance compliance; 2) be asked about patch adherence and pi[INVESTIGATOR_898764]; 3) record date of patch application on calendars, reviewed at lab visits; 4) bring 
used and unused patches to visits; 5) be given extra patches for immediate replacement;  and 6) Serum Levels 
of E2 and P4  will be collected at each session to both confirm compliance and that exogenous horm ones 
replicate physiologic4 luteal phase levels.  
 
Specific Rational for Route and Dose of Estradiol (E2).  By [CONTACT_898819]-pass metabolic effects of oral 
estrogen, transdermal E2 creates more stable blood levels and a more physiologic profile of E2 relative to its 
metabolites estrone and estriol169-171. Transdermal E2 also has a superior safety profile than oral estrogen for 
thromboembolic and metabolic risk172-174. The use of a 7 day transdermal system provides significantly more 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 10 
 stable concentrations and fewer patch adherence problems than twice weekly patches175. Climara® 7 day 
patches will be employed because the adhesive layer of the matrix patch (vs. reser voir systems) consists of 
polymeric acrylate or vinyl acetate in which the E2 molecules are distributed to conti nuously releases E2, which 
is transported across the skin leading to sustained circulating levels of E2 during ea ch 7-day period. Levels of 
E2 achieved in pharmacological studies with Climara patches at the .1mg/24hrs do sage correspond roughly t o 
normative luteal levels of E24. Climara achieves peak levels of E2 within 24 hours.  
 
Specific Rationale for Route and Dose of Progesterone (P4).  No transdermal P4 is available. Although 
transdermal synthetic progestins are available, these molecules have a high af finity not only for the progesterone 
receptor but also for the androgen and mineralocorticoid receptors, limiting the ir usefulness for testing our 
hypotheses. Therefore, 200mg oral prometrium  will be dosed daily (100mg each morning, 100mg each 
evening) to achieve luteal levels P44 to create more steady-state levels and minimize the greater variability  
(peaks and troughs) that can occur with the oral route. Prometrium peaks wit hin 3 hours and declines throughout 
the next 24 hours.  
 
Other possible hormone manipulations  were considered: a) mid-luteal administration of human chorionic 
gonadotropin to extend the luteal phase by [CONTACT_898820], which would not isolate E2/P4 
withdrawal from other hormones; b) mid-luteal GNRH antagonist administrati on to precipi[INVESTIGATOR_898765], 
which would have a menopausal side effect profile and a precipi[INVESTIGATOR_898766] E2/P4 that would not resemble 
perimenstrual E2/P4 decline; c) use of continuous oral contraceptives to eliminate cyclical hormone flux, which 
would stabilize E2/P4 in follicular phase ranges and not allow modeling of luteal phase levels.  
 
2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1 KNOWN POTENTIAL RISKS  
 
1) Psychological Symptom Assessment  
 
Clinical interviews and self-report assessments contain questions regarding sen sitive personal information, 
including severe psychological symptoms such as suicidal and other impulsive behaviors (e.g., sub stance 
abuse). As a result, participants may become upset or embarrassed when discussing curren t or past 
distressing life events and behaviors. On the other hand, recent evidence suggests t hat research questions 
pertaining to potentially distressing topi[INVESTIGATOR_898767], suicidali ty, and sexual or physical 
abuse do not significantly increase distress or acute suicide risk in women who report these issues3,164. The 
chance of increased distress is necessary in order to assess how symptoms change in response to 
perimenstrual hormone withdrawal (vs. stabilization). 
 
2) Effects of the Ovarian Hormone Stabilization Protocol on Mood/Anxiety and Behavi or 
 
Mood/Anxiety . As the population being studied in this protocol will have elevated psychiatric symptoms, and  
as ovarian hormone changes are implicated in depressive symptoms in some women39,50, it is possible that 
adverse mood reactions may occur (1) during the administration of ovarian hormon es in the stabilization 
condition or (2) naturally during the placebo (natural) perimenstrual wit hdrawal condition. However, because 
the hormone manipulation mimics (i.e., stabilizes) the luteal hormone levels that w omen naturally 
experience4, the study is not expected to pose any greater risk to participants than what they 
experience in daily life.  Furthermore, although withdrawal from exogenous E2/P4 (which will mimic norm al 
late luteal phase hormone withdrawal given that exogenous levels will mirror no rmal luteal physiologic ranges) 
could elicit negative mood changes, these would not be expected to be any more severe than those that would 
otherwise have arisen from normal perimenstrual hormone withdrawal —that is, we will have simply delayed the 
normal withdrawal process. 
 
Suicidality . As detailed above, the population will be recruited to achieve a population of  women that is 
simultaneously: (1) experiencing recent suicidal ideation , yet (2) at acceptably low1,2,149 current risk for 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 11 
 suicidal crisis/attempt  based on an assessment conducted during a screening visit (see Experimental 
Eligibility Table in later section ). Because ovarian hormone changes are implicated in psychiatric symptoms 
in some women39,50, and because such symptoms may increase suicide risk, it is possible that increases in 
suicidality may occur (1) during the administration of ovarian hormones in stabiliz ation conditions or (2) 
naturally during the placebo (natural) perimenstrual withdrawal condition. However, because the hormone 
manipulation mimics (i.e., stabilizes) the normal physiologic range of luteal hormone l evels4 that 
women naturally experience, the stu dy is not expected to expose participants to greater risk for 
suicidality than what they experience in daily life.    
 
3) Hormone Side Effects  
 
We do not expect any adverse side effects associated with the hormonal manipulation f or the following 
reasons: First, we will be administering the physiologically relevant steroid hormones (estradiol and/or 
progesterone) and not the substituted steroids (such as ethinyl estradiol or norethindrone) prese nt in many oral 
contraceptives and which have been reported to have a potentially more serious profile of side effects176-179. 
Second, prior exogenous hormonal studies (or E2, P4, or a combination) conduct ed in [CONTACT_187951]’s lab at the 
NIH that induced substantially more elevated hormone concentrations and a more precipi[INVESTIGATOR_898768], and no severe psychological adverse events were reported.  
 
SIDE EFFECTS OF ESTRADIOL  
 
The most frequent side effects associated with estradiol use include: 
- breast tenderness (occurs in 29% of patients) 
- abdominal cramps (occurs in 16% of patients) 
- headache (occurs in 13% of patients) 
- edema (swelling) (occurs in 10% of patients) 
- nausea (occurs in 6% of patients) 
- acne (occurs in 3 – 12% of patients) 
- skin rash or irritation may also occur at site where the patch is placed (occurs in 3 - 12% of 
patients) 
 
Rare side effects (<1%) include: 
- jaundice (yellowing of skin) 
- increased blood pressure 
- worsening of migraines or asthma 
- enlargement of uterine fibroids 
- intolerance to contact [CONTACT_13276] 
- dizziness 
- changes in appetite and weight 
 
E2 is widely prescribed; given the modest dose and duration administered here, sev ere adverse events are 
unlikely. Given our plans to administer transdermal E2 to women: (1) fo r only 14 days, (2) no older than 45 
years of age, (3) who are currently regularly menstruating and medically  healthy, and (4) who are at no greater 
than average risk for cancer and venous thromboembolism, the risk of serious adverse events is 
exceedingly low. 
 
 
SIDE EFFECTS OF PROGESTERONE 
 
The most common side effects associated with progesterone include: 
- breast tenderness (occurs in 16% of patients) 
- dizziness (occurs in 24% of patients) 
- abdominal crampi[INVESTIGATOR_007] (occurs in 20% of patients) 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 12 
 - headache (occurs in 16% of patients) 
- viral infection (occurs in 12% of patients) 
- joint pain (occurs in 12% of patients) 
- diarrhea (occurs in 8% of patients) 
- menstrual bleeding, sometimes consistent with a heavy menstrual period (occurs in  20-30% of 
patients) 
- drowsiness (occurs in 9% of patients) 
 
Rare (<1%) side effects include: 
- vaginal discharge 
- chest pain 
- abdominal bloating  
 
Progesterone is widely prescribed, with indications including dysfunctional uterine bl eeding, endometriosis, 
mastodynia, galactorrhea, and precocious puberty180. In our recent study, a dose of 300 mg of oral micronized 
progesterone (higher than that given in the present study) was given to a sample of women with premenstrual 
mood disturbance and was well tolerated by [CONTACT_809813]146. Given the modest dose and duration used in the 
present trial, severe adverse events are unlikely. 
 
4) Confidentiality   
 
A breach of confidentiality could indicate to others a participants’ history of psychiatric symptoms. 
 
5) Venipuncture  
 
Standard risks associated with venipuncture are present during the laboratory testing ses sions. 
 
2.3.[ADDRESS_1259651] a pathophysiologic mediational model  in 
which late luteal (perimenstrual) E2/P4 withdrawal (vs. experimental luteal E 2/P4 stabilization via exogenous 
transdermal E2 and oral micronized P4) increases suicidal desire (via increased hopelessness and negative  
social appraisals) and suicidal acti on capacity (via reduced inhibitory control and increased threat sensitivity). 
We predict that natural E2/P4 withdrawal (compared to stabilization) will increase reports of suicidal desire 
(partially mediated by [CONTACT_898821]) and 
action capacity (partially mediated by [CONTACT_898822]). 
 
4 STUDY DESIGN AND ENDPOINTS 
 
4.1 DESCRIPTION OF THE STUDY DESIGN 
 
This is a single-center study; there is no phase designation because it is a mechanistic e xperiment 
with agents (E2,P4) that is commonly used in clinical practice. 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 13 
 Participants:  30 female outpatients with recent suicidal ideation but low1,2 imminent  risk for suicide attempt  
(see Human Subjects  section for details) receiving treatment as usual from a mental health provide r at UNC 
will be recruited. Women must: be [ADDRESS_1259652] normal menstrual cycles (25-35 days), not 
pregnant (verified with urine screens), breastfeeding, or trying to get pre gnant, not taking hormones, no history 
of serious medical illness, normal weight (BMI 18-28 kg/m2), and low ris k for thrombotic events (factor V Leiden 
mutation based on family history). Use of psychotropic medications are expected i n the majority of participants.  
Most outpatients with suicidality take psychotropic medications; therefore, to increase feasibility and 
generalizability, medication use will be carefully measured daily and covaried i n analyses if common enough.   
Psychiatric Diagnoses . Women will undergo initial SCID-I and SCID-II interviews. History of manic epi[INVESTIGATOR_1865], 
psychosis (except dissociation), or substance abuse disorder will be exclusionary due to increased risk of suicidal 
crises1,149. Additionally, a self-report history of treatment for postpartum depressi on or a current diagnosis of 
premenstrual dysphoric disorder will be exclusionary, since these reproductive mood disorders cou ld be 
characterized by a different pathophysiological pattern of sensitivity to ovarian steroid flux150. On the basis of 
work by [INVESTIGATOR_124]. Prinstein108, we expect that 50 - 75% of our sample will meet criteria for major or persistent depressive 
disorder, ≥ 50% will meet  criteria for BPD, and 
≥ 25% will meet criteria for an anxiety disorder.  
 
Study Design (see figure at right; top = 
naturally occurring cyclicity of E2/P4 under 
placebo, bottom = E2/P4 withdrawal 
prevention using exogenous E2/P4) . THIS IS 
NOT A CLINICAL EFFICACY TRIAL.   However,   
a within-person crossover RCT design with 
transdermal 17β -E2 and oral micronized P4 (or 
placebo) will investigate the pathophysiologic 
role of perimenstrual steroid withdrawal in 
suicidal desire and action capacity. Consenting 
participants will be trained in the protocol, 
including urine ovulation testing (LH surge 
preceding ovulation 24-36 hours), the daily 
phone assessment, and the patch/pi[INVESTIGATOR_898769]. 
Using a double-blind, within-subject cross-
over design , participants will be randomized as 
to the order in which they receive (1) active 17β -
E2 + P4 or (2) placebo patch/pi[INVESTIGATOR_3353]. The UNC 
Investigational Drug Services will manage the 
randomization and dispensing of medications. 
During the E2/P4 stabilization condition, for two 
weeks , participants will wear a weekly patch 
(Climara®) delivering 0.10 mg E2/24 hrs —a 
dose tolerated by > 94% of the 200+ women in 
[CONTACT_898869]’s recent study (NIMHR01 087619 )— 
and will take oral progesterone (Prometrium®) at a dose of 2 00 mg (100mg each morning, 100mg each evening) . 
A higher dose (300mg/day) was well tolerated by 100% of premenopausal women in [CONTACT_898869]’s prior research 
(NIMHR01051246). These doses will achieve (stabilize) luteal E2/P4 levels4.  
 
Timing of Hormone Administration.  Based on home urine ovulation testing, participants will apply the first 
seven-day transdermal E2 patch (or placebo patch) and begin daily oral P4 (or or al placebo) seven days after 
urine-confirmed ovulation (cycle 1, +7) to coincide with a time in the natural cycle whe n E2/P4 are elevated. The 
goal of the active E2+P4 manipulation is to extend and maintain the mid-luteal phase hormone profile  
beyond the point in the cycle that would normally be associated with natural E2/P4 wit hdrawal. In the active 
E2/P4 condition, the luteal phase hormone profile will be maintained for 14 days by [CONTACT_2931] a new patch on day 
8 (extended luteal phase spanning +7 to +21 in lower panel), preventing natural withdraw al and stabilizing E2/P4 
in physiologic4 luteal range. The placebo condition uses the same patch/pi[INVESTIGATOR_898769].  
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259653] day of patches/pi[INVESTIGATOR_898770] [ADDRESS_1259654] pat ch/pi[INVESTIGATOR_4382] (phone symbols in figure above ). Three 
lab sessions will measure mediating constructs using behavioral tasks. In each condition, lab visits will occur on 
days +7, +14, and +[ADDRESS_1259655] whether prevention of E2/P4 withdrawal is 
associated with mediating behavioral constructs and suicide risk, we will compare tasks  and interviews in LAB PL2 
with LAB EXP2.  
 
Blinding of Participants and Staff. All study staff performing assessments will remain blinded to conditi on. The 
natural within-woman variation in menstrual cycle length from one cycle to another will help maintain the 
participant blind.  Few women have regular [ADDRESS_1259656] on women’s 
symptoms (of note, this is scientifically accurate39). Finally, although some women may become unblinded later 
in the extended hormone phase, work by [CONTACT_898823]144. 
 
Lab Construct Measures . Each computerized task is scored using within-task comparisons, controlling f or 
experience- or training-related changes in response time. Hopelessness will be measured via the Future 
Thinking Implicit Relational Assessment Procedure (FT-IRAP)151, in which participants respond with true or false 
to pairings between “I expect” and “I don’t expect” with sets of negative (e.g., worr y, sadness) and positive (e.g., 
enjoyment, happi[INVESTIGATOR_008]) events. Greater latency to optimistic/hopeful, and l ower latency to pessimistic/hopeless 
pairings indicate implicit hopelessness151. Validity : Performance predicts clinical hopelessness and 
depression151. Negative Social Appraisals will be measured using the Social Acceptance-Rejection Implicit 
Association Test (SAR-IAT)152, in which participants respond to pairings of self words (e.g., I, me)  and other  
words (e.g., them, you) with words indicating social acceptance (e.g., included) or social  rejection (e.g., rejected). 
Response times to pairings indicate the strength of implicit self-with-acceptan ce or self-with-rejection 
associations. Validity: Performance predicts explicit social appraisals and heightened negative affect in  social 
interactions per clinical interviews152. Inhibitory Control  will be measured using performance on the Stop-Signal 
Task (SST)153, an index of the ability to withhold a prepotent response. Validity: Performance predicts prefrontal 
cortex function and lower impulsive clinical outcomes153. Threat Sensitivity will be measured as attentional bias 
for threat pi[INVESTIGATOR_337641] a Dot Probe Task (DPT)154. Validity: Attentional bias to threat on this task is linked to anxiety 
disorders155 and multimodal indices of threat sensitivity in daily life154,156.  
 
Daily Telephone Symptom Measures (PRIMARY AND  SECONDARY ENDPOINTS) : Depressive Symptoms 
and Hopelessness using the 10-item short form of the CES-D161 and the Beck Hopelessness Scale162, Anxiety 
Symptoms (reflecting Threat Sensitivity) using the 6-item short form of the Patient-Reported Outcome 
Measurement Information System (PROMIS) Anxiety scale163; Impulsive Symptoms  using a five item version 
of the UPPS -P Lack of Premeditation (i.e., classic impulsivity) subscale158; and Rejection Sensitivity 
Symptoms (reflecting social appraisals) using two items with high item-total corr elations from the Social 
Evaluation subscale of the State Self-Esteem Scale157. Each of these inventories has been  extensively validated 
for the measurement of the target construct. Suicidal desire a nd action capacity will be measured daily using 
a shortened version of the SITBI160.  
 
Participant Safety: Emergent changes in suicidality will be managed using the structured University of 
Washington Risk Assessment and Management Protocol (UWRAP)3,164, a safety protocol recommended by 
[CONTACT_898824]3. If imminent risk for suicide 
emerges and cannot be satisfactorily managed by [CONTACT_898825] (as determined by [INVESTIGATOR_124]. Prinstein), the 
protocol for discontinuation will be followed. However, because the manipulation mimics luteal E2/P4 levels that 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 15 
 women naturally  experience,  the hormonal manipulation is not expected to pose greater risk than a normal4 
menstrual cycle —the risk will simply be shifted in the stabilization condition.  
 
 
4.2.1 PRIMARY ENDPOINT 
 
The primary endpoints (described below ) of this mechanistic study are suicidal ideation and planning score 
differences between placebo days and stabilization days on the SITBI interview . These were chosen given 
their strong predictive validity in epi[INVESTIGATOR_9037] .  
 
(1) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of SITB 
Suicidal Ideation subscale score  
 
(2) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of SITB 
Suicidal Planning subscale score  
 
 
4.2.2 SECONDARY ENDPOIN TS 
 
The secondary endpoints of this study include the daily telephone measures as follow s:  
 
(6) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of BHI 
Hopelessness Score  
 
(7) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of CES-D 
Depression Total Score  
 
 
(8) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of UPPS- P 
Lack of Premeditation Impulsivity subscale  
 
(9) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of PROMIS 
Anxiety Total Score  
 
(10) Mean Within-Person Condition Difference (7 final placebo days – 7 final stabilization days) of 
SSES Social Evaluation/ Rejection Sensitivity subscale  
 
 
4.2.[ADDRESS_1259657] meet all of the following general criteria:  
• Provision of signed and dated informed consent form  
• Stated willingness to comply with all study procedures and availability for the duration of the study  
• Ability to take oral medication and be willing to adhere to the medication regi men  
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259658] be biologically female  and between the ages of 18-45 years .  
o Justification : Women younger than [ADDRESS_1259659] normal menstrual cycles  between 25 and 35 days. 
o Justification : Abnormal menstrual cycle lengths or variability in lengths could introduce error 
variance into the experiment, and could reduce confidence regarding the timing of  the 
experimental manipulation to cycle events. 
 
3. Must be under the current care  of an outpatient mental health provider. 
o Justification : Because we intend to recruit women with current suicidality, engagement with a 
mental health provider is required as a protective measure to ensure that partici pants have 
access to treatment if needed. 
 
4. If the woman has children, she must be at least 1 year postpartum . 
o Justification : The postpartum period can be characterized by [CONTACT_898826]; therefore, postpartum women may introduce error variance into the experiment . 
 
5. Must be of normal weight  (BMI between 18-29 kg/m2); measured at the enrollment visit. 
o Justification : Responses to doses of hormones may vary by [CONTACT_898827]. 
 
6. Must report at least some recent suicidal ideation (in the past month) at enrollment.  
 
• Justification : As reviewed in the research strategy, the purpose of the study is to examine t he 
impact of natural perimenstrual hormone withdrawal (vs. prevention of ho rmone 
withdrawal/stabilization of E2/P4) on within-person changes in suicide risk. The present 
sampling strategy ensures  generalizability3 of our findings to clinical populations of interest 
and will also prevent a  floor effect  (i.e., zero-inflation of daily outcome measures and 
associated limitations in power to detect effects) on primary daily outcome measures ( e.g., 
mediating behavioral constructs, suicidality).  
 
7. Must be categorized as having acceptably low imminent risk for suicidal crisis/attempt according 
to established clinical and research guidelines149 (see Eligibility Table), which have been adapted for 
the current study in collaboration with the co-mentor, [CONTACT_898870]. As co-m entor [CONTACT_898870] notes in 
his 2014 methodological paper on research-based suicide risk assessment2, evaluation of imminent 
risk of suicidal crisis/attempt is a complex clinical task, requiring integr ative consideration of a variety of 
factors (including: general clinical presentation, ideation severity, frequency, recency,  and associated 
consideration/intent; access to suicidal means; previous attempts and gestures; presence of suicidal 
planning, recent stressors, frequency of contact [CONTACT_898828];  and presence of social 
support). Therefore , our specific criteria for delineating whether a participant is eligible are based on an 
evidence-based determination2,149 that the participant is at acceptably low  imminent risk of suicidal 
crisis/attempt . These decisions will be based on responses to a variety of questions from the  SITBI 
and Severity of Suicidal Ideation Interview (clinical interviews at the beginning of an enrollment visit).  
 
o Justification:  Individuals with current suicidality are not necessarily at imminent risk for 
suicidal crises/attempt  (i.e., their risk is manageable on an outpatient basis through freq uent 
clinical contact, such as the daily calls in the present study). Because the hormon e protocol 
simply prolongs the physiologic luteal hormone profile, they are not expected to expose 
participants to additional risk of suicidal crisis beyond what they would naturally  experience 
during their typi[INVESTIGATOR_898771]. However, out of an abunda nce of caution, we will 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 17 
 exclude women with elevated imminent risk for suicidal crisis/attempt  (determined by 
[CONTACT_898829]2,149). Individuals with histories of suicidality often 
have ongoing, habitual thoughts about death or suicide that are highly distingui shable from  
imminent risk for suicide attempt1,149,166. In further support of this notion and of the feasibility 
of recruiting this population, it should be mentioned that up to 1/3 of the Am erican population 
experiences suicidal ideation at some point in their lives166, yet less than .01% die by [CONTACT_898830]149,166.  
 
 
 
 
 
SPECIFICS OF SUICIDE RISK-RELATED ELIGIBILITY CRITERIA  
 
The study will include only women with current suicidal ideation (past-month endorsement of suicidal 
ideation) in order to maximize generalizability to our clinical population of interes t. We hypothesize that natural 
perimenstrual withdrawal from ovarian hormones will be associated with significant but  transient shifts in 
continuously-estimated suicide risk that are not expected to escalate to the level of suicidal 
crisis/attempt  (due to the exclusion of certain women at highest risk for attempt, as noted bel ow). In order to 
minimize the risk of suicidal crises during the study, we will exclude women who meet evidence-based 
criteria2,149 for imminent risk of acute suicidal crisis/attempt . 
 
The goal of these exclusion/inclusion criteria is to minimize  the risk that a participating woman will 
demonstrate imminent risk of suicidal crisis/attempt during the study. The determ ination of acceptably low 
current risk of suicidal crisis/attempt will be carried out in multiple steps, as follows: 
 
1. First, women must pass a phone screen in which they will report on their previous psychi atric 
diagnoses and recent history of suicide attempts. At that juncture, the follow ing criteria will be applied:      
a. A woman will be excluded if she reports a suicide attempt or any concrete suicida l planning in 
the past [ADDRESS_1259660] three months 
following an initial attempt1,149. 
b. A woman will be excluded if she reports a history of more than one suicide attempt, as multiple 
attempts represent a uniquely potent risk factor for additional suicidal cri ses/attempts1,149. 
c. A woman will be excluded (and referred) if she reports that she does no t currently visit a mental 
health provider (psychiatrist, therapi[INVESTIGATOR_541]) at least once every 3 months1.  
d. A woman will be excluded if she reports any extreme external stressors (e.g., death  of a loved 
one, loss of employment) in the past month, as extreme stressors drastically increase t he risk of 
suicidal crisis1,149. 
e. A woman will be excluded if she reports a history of clinical diagnosis w ith manic epi[INVESTIGATOR_1865], 
psychotic symptoms, or substance use disorder, as these disorders reduce predictability and 
increase likelihood of suicidal crises/attempt149.  
 
2. Second, women must pass an in-person eligibility screening at the beginning of an  enrollment visit, in 
which they will complete a clinical interview designed to more thoroughly assess the r isk factors 
described in 1a-1e above, as well as additional determinants of suicide risk outlined in Eligibility Table. 
a. Eligibility criteria in 1a-1e above will again be re-assessed and applied.  
b. Using a clinical interview based on the SITBI interview160 and the Scale for Suicidal Ideation 
interview168, the PI [INVESTIGATOR_898772] a variety of risk factors for suicidal crisis and 
evaluate whether a woman has acceptably low1,2,149 imminent risk of suicidal crisis/attempt using 
the decision rules described in the leftmost column in Eligibility Table and summa rized below: 
• The evidence-based determination of acceptably low risk1,2,149 of suicidal 
crisis/attempt will be based on the count of positive findings in each Row of 
Eligibility Table (see next page), as follows: No positive findings in Row 5; No 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 18 
 greater than 1 positive finding in Row 4; No greater than 2 total positive fi ndings 
in Rows 3 + 4; No greater than [ADDRESS_1259661]. Eisenlohr-Moul (the PI) will review the results of each eligibility visit interview wit h [CONTACT_898871] at weekly meetings (see Training Plan and Co-Mentor Letter) t o verify that the individual 
demonstrates acceptably low1,2,149 imminent risk of suicidal crisis/attempt before approving participation 
in the experiment. Should Drs. Eisenlohr-Moul and Prinstein determine the patient i s at imminent risk of 
suicidal crisis/attempt despi[INVESTIGATOR_898773], the pat ient will not continue 
with participation. However, should [CONTACT_898870] agree that the patient indeed demonstrates acceptably 
low1,2,149 risk of suicidal crisis/attempt as outlined in Eligibility Table, the participant will continue with 
randomization and participation in the study. 
 
4. Note that ongoing participant suicide risk monitoring and management is described in la ter sections. 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 19 
 EXPERIMENTAL ELIGIBILITY TABLE 
 
The goal of the suicide-related exclusion/inclusion criteria (outlined below) for the study is t o minimize  the risk that a participant will experience an 
acute suicidal crisis or attempt suicide during the study. Evidence-based criteria w ere developed in collaboration with the co-mentor, Dr. 
Prinstein1,2,149. History of mania, psychosis, or substance abuse disorder will also be exclusionary. Table notes: Recen t = In the past month. MHP = 
Mental Health Provider. 1SITBI items 3a, 3b, 4a, 4b, 4c. 2SITBI items 1a, 1b, 1c, 1f, 2c. 3SITBI items 2a, 2b.  
 
 ROW Suicide 
Attempts1 Suicidal Thoughts2 Recency 
of Last 
Suicidal 
Planning3 Current 
Access to 
Means  Recent 
Stressors /
Loss Current 
Frequency 
of MHP 
Contact  [CONTACT_898831]      
[ADDRESS_1259662] 
year Less than 
monthly 1f=1 2c=1 Never No Access 
to Means None >1x/ 
month Multiple 
Strong 
Supporter
s 
2 
No more than 3 
total positive 
findings allowed 
in Rows 2,3, +[ADDRESS_1259663] 
month ~1x/ 
month 1f=2 2c=2 >[ADDRESS_1259664] year ~1x/ 
month One 
Strong 
Supporter 
or multiple 
supports 
3 
No more than 2 
total positive 
findings allowed 
in Rows 3 + [ADDRESS_1259665] 
week ~1x/ week 1f=3 2c=[ADDRESS_1259666] 3 
months ~1/ 
[ADDRESS_1259667] 6 
months Now >1x/ 
week 1f=4 2c=[ADDRESS_1259668] 1- 2 
months ~1x/ 
3 months No 
Support 
5  
No positive 
findings allowed 
in Row 5 >[ADDRESS_1259669] 3 
months     <[ADDRESS_1259670] month <1x/ 
3 months  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 23 
 5.2 PARTICIPANT EXCLUSION CRITERIA 
 
Any individual meeting any of the following exclusion criteria at baseline will be 
excluded from the study: 
 
1. Must not be  pregnant, breastfeeding, or trying to become pregnant . Pregnancy 
status will be confirmed using urine pregnancy test at the enrollment v isit and again at 
the first visit of the second condition. Women will be encouraged to use a barrier method 
of birth control during the study. 
o Justification : Administration of ovarian hormones to a pregnant woman could 
negatively influence the pregnancy in a variety of ways, including risks to  the 
health of the fetus. 
 
2. Must not be taking any form of exogenous hormones  or IUD, and must have ended 
previous use of hormonal preparations at least one month prior to the study. 
o Justification : The use of additional exogenous hormones poses safety risks and 
would undermine experimental control of hormones.  
o Women will be required to use licensed barrier methods of contraception 
during study participation; if they are unable to commit to this 
responsibility, they will not be eligible for participation . 
 
8. Must report no personal history of any chronic medical condition , including but not 
limited to metabolic or autoimmune disease, epi[INVESTIGATOR_002], endometriosis, canc er, diabetes, 
cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease, and no personal 
or first degree family history of thromboembolic events. 
o Justification : Administration of exogenous hormones to women with these 
chronic medical conditions may increase the risk of an adverse health-related 
response to hormones. Further, the purpose of the present study is to determine 
the impact of hormonal stabilization (vs. natural withdrawal) in otherwise 
physicall y healthy  women.  
 
9. Must not currently smoke cigarettes . 
o Justification : Administration of ovarian hormones to women who smoke may 
increase the risk of thromboembolic events.  
 
10. Must not report a history of clinical diagnosis of postpartum depression or premens trual 
dysphoric disorder (Note: PMDD diagnosis must have been made based on prospective 
daily ratings).  
o Justification : Some evidence would suggest that the pattern of perimenstrual 
symptoms that have been linked with these reproductive mood disorders could  
differ meaningfully39 from that which we be expect in the more general clinical 
population of women with suicidality8. Because these distinctions are not yet 
clear, women with a self-reported history of clinical diagnosis with these 
disorders will be excluded.  
 
11. Must not report any history of manic epi[INVESTIGATOR_1865], psychotic symptoms, or substan ce use 
disorder.  
o Justification : These factors are known sources of variability in suicidality and 
would therefore introduce error into our models as well as increasing the risk that 
a participant would experience a suicidal crisis during the study1,149.  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259671] access to recruitment pathways. Second, we w ill 
advertise to the Raleigh, Durham, Chapel Hill (i.e., the “Triangle”) commun ity using email and 
listserv advertisements (sent to the UNC-Chapel Hill community), flyers in loca l businesses and 
buses, and radio/newspaper/website ads.  
 
Potential participants will complete initial eligibility screening by [CONTACT_18623] a secu re online 
questionnaire. 
 
No more information will be asked of participants than necessary to obtain el igibility information 
and to contact [CONTACT_898832] a screening/enrollment visit. At this 
initial visit, the PI ([CONTACT_704968]-Moul) will obtain written informed consent for furt her screening 
regarding suicidality from those individuals who pass the initial telepho ne and questionnaire 
screenings and are interested in participating. This consent will inform participants re garding the 
nature of the questions to be asked. If the participant consents, the Self-I njurious Thoughts and 
Behaviors Interview160 and the Scale for Suicidal Ideation Interviews168 will be administered. If 
the participant is not eligible for the study following the screening (see det ails above), they will 
be dismissed and referred for treatment as necessary. If they are eligible, [CONTACT_704968]-Moul 
will obtain additional written informed consent for participation in the larger study (i.e., the 
screening visit will become the enrollment visit). During the consenting process for the larger 
study, all of the applicable consent forms will be reviewed with each individual, and they will be 
given as much time as they would like to discuss their participation with thei r significant others 
and decide whether to participate.  
 
INCLUSION OF WOMEN AND MINORITIES 
 
Men will not be included in this study, given the stated purpose of examining ovaria n 
hormone withdrawal as a mechanism of suicidal risk in women. 45 women will be included in 
the study. 
The UNC Center for Women’s Mood Disorders has a strong commitment to the 
enrollment of minority women in research projects, and this commitmen t will be reflected in this 
study. As shown below, the ethnic and racial composition of the population from which subject s 
will be recruited, including Orange, Durham, and Wake counties, is similar to the  population of 
the [LOCATION_002] as a whole.  
 
 
 
 
 
 
 
 
 
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 25 
 Race/Ethnicity Wake Durham Orange Adjusted 
Average 
White  70% 54% 78% 69% 
Black or 
African 
American  21% 39% 12% 24% 
American 
Indian/Alaska 
Native  1% 1% 1% 1% 
Asian  6% 5% 7% 6% 
Hispanic or 
Latino Origin  10% 14% 8% 11% 
 
 The PI [INVESTIGATOR_898774]. We have conservatively estimated our ability to recruit a sample that is 76% White, 
20% Black or African American, 4% Asian, and with 8% identifying as Hispanic  or Latina.   
 
Recruitment Plan for Minorities : We realize, however, that specialized efforts wi ll be needed to 
meet these goals.  Because minorities underutilize mental health care, the PI [INVESTIGATOR_898775]. [CONTACT_898872], primary mentor, has a long-standing track record of successful recruitm ent of African 
Americans (our largest minority population) into clinical research studies.  In her mos t recent 
ethnic differences research (RO1-DA13705), she was successful at recruiting over 125 African 
American men and women (50% of the entire sample) and in each of her current studi es (RO1s 
MH087619 and MH099076), 30% of the women enrolled identify as African American.   W e will 
employ the strategies that have proven successful in her prior studies.  The single m ost 
effective strategy involves the use of minority research staff in t he recruitment and retention 
process.  Other strategies involve the use of culturally sensitive language in advert isements, 
including assurances that the study involves no experimental drugs or devices.  We w ill also 
advertise in periodicals targeting African American populations and work with community-based 
minority programs.  Statistics will be kept throughout the study document ing recruitment 
strategy and enrollment rates, allowing the PIS to adjust initiatives accordingly .  Should 
additional initiatives be necessary, we will work directly with leaders from the African  American 
community. 
 
JUSTIFICATION FOR INCLUSION OF INDIVIDUALS WITH CURRENT SUI CIDALITY 
 
As reviewed in the study background and rationale, the purpose of the study is to examine the 
impact of natural perimenstrual hormone withdrawal (vs. prevention of ho rmone 
withdrawal/stabilization of E2/P4) on within-person changes in suicide risk. The present  
sampling strategy ensures  generalizability3 of our findings to clinical populations of interest 
(i.e., not simply depressed women, but those with suicidality) and will also prevent a  floor 
effect  (i.e., zero-inflation of daily outcome measures and associated limitations in power to 
detect effects) on primary daily outcome measures (e.g., mediating beha vioral constructs, 
suicidality).  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 26 
  
Individuals with current suicidality are not necessarily at imminent risk for suicidal 
crises/attempt  (i.e., their risk is manageable on an outpatient basis through freque nt clinical 
contact, such as the daily calls in the present study). Because the hormone prot ocol simply 
prolongs the physiologic luteal hormone profile, it is not expected to expose participants to 
additional risk of suicidal crisis beyond what they would naturally experience during their typi[INVESTIGATOR_898776]. However, out of an abundance of caution, we wil l exclude women 
with elevated imminent risk for suicidal crisis/attempt  (determined by [CONTACT_898833]2,149). Individuals with histories of suicidality often have ongoing, 
habitual thoughts about death or suicide that are highly distinguishable from  imminent risk for 
suicide attempt1,149,166. In further support of this notion and of the feasibility of recruiting this 
population, it should be mentioned that up to 1/3 of the American population experien ces 
suicidal ideation at some point in their lives166, yet less than .01% die by [CONTACT_898834]149,166.  
 
RETENTION OF INDIVIDUALS WITH SUICIDALITY 
 
Although a variety of exclusion criteria will be applied, the PIs recent work has prepared her to 
recruit, retain, and maintain the safety of108 women with suicidal ideation but low2,[ADDRESS_1259672] completed 85% of daily email 
surveys; given larger incentives for shorter daily contacts, we expect a higher response rate. The 
PI [INVESTIGATOR_898777] (using the same psychiatric exclusion criteria) in 
her new clinical fellow role with [CONTACT_898870], who has great success in the recruitment, phone  
engagement, and retention of suicidal outpatients108. Empi[INVESTIGATOR_3675]-supported strategies167 for 
retention will include study branding, frequent contact, monetary rewards, and graduated 
compensation schedules.  
 
 
Study subjects will receive the following monetary incentives: 
 
$100 pay for one enrollment visit 
 
$50 pay for each laboratory testing session x 6 laboratory sessions = $300 possible testing visit 
pay 
 
$200 pay for daily phone calls (prorated at $[ADDRESS_1259673] withdraw s) 
 
= For a total possible compensation of $ [ADDRESS_1259674]. An investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), or other medical condition or situation occurs su ch that 
continued participation in the study would not be in the best interest of the participant as 
determined by [CONTACT_898835]. Eisenlohr-Moul in collaboration with [CONTACT_898873] and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 27 
 (severe mood deterioration, severe changes in suicidality), [CONTACT_187951] (hormonal side 
effects). [CONTACT_187951] may consult [CONTACT_99780] with regard to gynecologic issues as 
necessary.  
 
• The participant meets an exclusion criterion (either newly developed or not previ ously 
recognized) that precludes further study participation. 
 
 
5.4.[ADDRESS_1259675]. 
Prinstein (see Appendix for UWRAP). However, if a participant is judged to be at imminent risk 
of suicide and therefore in need  of immediate hospi[INVESTIGATOR_059] , the participant will be immediately 
discontinued from participation and hospi[INVESTIGATOR_057]. Our offices are in close proximi ty to UNC 
emergency department, and participants requiring immediate emergency care can easily be 
transferred there. An immediate follow- up phone call to the participant’s mental health  provider 
alerting them to the change in symptoms (see information below regardin g consent to provider-
researcher communication) will occur immediately. If the participant is taking  study medication 
currently, [CONTACT_187951] will immediately be contact[CONTACT_898836]. If it is revealed 
that the participant is currently in the placebo condition, he will take no further action. How ever, 
if it is revealed that the participant was currently in an active hormone sta bilization condition, he 
will overs ee the subject’s discontinuation of the exogenous hormone  according to his best 
clinical judgment.  
 
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY 
 
At six month intervals, the study biostatistician ([CONTACT_898874] ) will test whether there are significant 
differences in the occurrence of moderate, severe, and serious AEs in the placebo vs. t he 
experimental condition with alpha set at .05. These results will be provided t o the Data Safety 
and Monitoring Board (DSMB) along with the summary report of enrollment.  
 
Administration of study agent will be halted when three serious AEs* determined to be 
“probably related”  (i.e., with new onset during study patches/pi[INVESTIGATOR_3353]) are observed . The PI 
[INVESTIGATOR_898778]. The DSMB will notif y the study sponsor and 
investigators immediately when the third severe event is reported and enrollment screens  will 
stop accepting new study participants. [CONTACT_898874] will again perform an unblinded statistical 
analysis to further determine whether active study medication (E2/P4) is significa ntly 
related to greater risk of AEs relative to placebo . All requested documentation will be 
provided to the DSMB. The DSMB will convene an ad hoc meeting by [CONTACT_898837]. The DSMB will provide recommendations for proceeding wi th the 
study to the PI [INVESTIGATOR_290665]. The study sponsor will inform all appropriate regulatory agencies of 
the temporary halt and the disposition of the study. 
 
The DSMB will consider stoppi[INVESTIGATOR_898779]. Xia: specifically, if the experimental hormone stabilization conditi on is 
associated with greater risk of severe or serious AEs than placebo, and there is evidence (as 
determined by [INVESTIGATOR_187898]) that such AEs are causally related to the study drug,  the study 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 28 
 will be terminated.  
 
*Notable examples of serious adverse events in the present study include development 
of a venous thromboembolism or suicide attempt.  
 
 
6 STUDY AGENT 
 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION 
 
6.1.1 ACQUISITION 
 
Both Climara patches (transdermal E2) and Prometrium pi[INVESTIGATOR_3353] (oral micronized P4) w ill be 
acquired through UNC Investigational Drug Services from their respective manufacturers .  
 
IDS will order climara + prometrium, placebo patches have been shipped, donated fr om Wisner.  
 
6.1.2 FORMULATION, APPEARANCE , PACKAGING, AND LABELING 
 
Please see attached inserts for information about active Climara patches (transdermal E2) and 
Prometrium (oral micronized P4). Both transdermal E2 and oral micronized P 4 are readily 
commercially available. Placebo patches and pi[INVESTIGATOR_3353] (both in stock at UNC IDS) are formulated 
and designed to be identical in appearance to these agents; all packaging and blinding wil l be 
accomplished via UNC Investigational Drug Services.  
 
6.1.[ADDRESS_1259676] STORAGE AND STABILITY 
 
Both Climara and Prometrium can be stored at room temperature for the duration of an 
individual’s study participation. Participants will be instructed to avoid exposing study 
drugs to extreme temperatures or humidity. More specific information about storage and  
stability can also be found in the attached inserts for Climara and Prometrium .  
 
6.1.4 PREPARATION 
 
All preparation will be handled by [CONTACT_898838] (IDS), w ho will blind and 
mask the study drugs. No further preparation will be required by [CONTACT_898839].  
 
6.1.[ADDRESS_1259677] ered orally in pi[INVESTIGATOR_898780]. 
 
6.1.7 STARTING DOSE AND DOSE ESCALATION SCHEDULE 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 29 
  
In the experimental arm, the dosages will be fixed and not changed.  
 
6.1.8 DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS 
 
If the PI [INVESTIGATOR_898781] a participant must be discontinued from the protocol 
(see Section 5.4.2), [CONTACT_187951] will be unblinded via IDS. If the par ticipant was on active 
E2/P 4, [CONTACT_187951] will supervise the subject’s discontinuation  from E2/P4. Regardless of the 
condition the participant was in, the PI [INVESTIGATOR_898782] (e.g., hospi[INVESTIGATOR_898783]). 
 
6.1.9 DURATION OF THERAPY 
 
The planned duration of active treatment is 14 days. All days in which participants use  patches 
and pi[INVESTIGATOR_898784], which accommodate 
unbalanced/missing data.  
 
6.1.10 TRACKING OF DOSE 
 
For patches (E2):  E2 patches will be applied (day +7 following ovulation) and changed (day 
+14 following ovulation) in the laboratory; therefore, no compliance issues are anticipated for 
E2.  One extra patch will be given to each participant in the case that the patch falls off. All used 
patches will be brought to the lab so that use of patches can be monitored. 
For pi[INVESTIGATOR_3353] (P4) : at the first lab visit, study staff will work with participants t o develop individualized 
methods for reminding the participant to take twice-daily study pi[INVESTIGATOR_3353], incl uding but not limited to 
email reminders, phone call reminders, text reminders, app-based reminders (with data stored  
locally only), pi[INVESTIGATOR_898785], calendar reminders, and stimulus control (e. g., putting study medication 
on bedside table. Women will bring in pi[INVESTIGATOR_898786].  
6.1.11 DEVICE SPECIFIC CONSIDERATIONS 
 
Not applicable.  
 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES 
 
Research staff pi[INVESTIGATOR_898787] . All unused pi[INVESTIGATOR_898788], who 
will return them to IDS. IDS will dispose of unused materials according to regulations. 
 
7 STUDY PROCEDURES AND SCHEDULE 
 
7.1 STUDY PROCEDURES/EVALUATIONS 
7.1.1 STUDY SPECIFIC PROCEDURES  
 
PHONE SCREENING 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 30 
  
Variable Interview 
Measure Self-Report 
Measure Task Measure 
Inclusion/Exclusion Criteria x - - 
Psychiatric Diagnosis Self-
reported 
Previous 
Diagnosis - - 
Suicidality Abbreviated 
SITBI - - 
 
 
ENROLLMENT VISIT – 1 VISIT @ 1.5 HRS 
• Timing: Can occur at any time provided that it allows for the participant to 
complete the protocol in the term of IRB approval.  
• Assessments Administered (see section 4.1 for Abbreviations): 
 
Variable Interview 
Measure Self-Report 
Measure Task Measure 
Vitals - - Height/Weight 
Urine Pregnancy Screen - - x 
Inclusion/Exclusion Criteria x   
Psychiatric Diagnosis SCID - - 
Suicidality Full SITBI - - 
Depression - CESD  - 
Hopelessness - BHI - 
Inhibitory Control - UPPS -P - 
Threat Sensitivity - STAI - 
Negative Social Appraisals - SSES  - 
 
LABORATORY TESTING VISITS – 6 VISITS @ 1.5 HRS 
• Timing: The three laboratory visits for each condition will occur on days +7, +14, 
and +[ADDRESS_1259678] (day 0). The acceptable windows will be 
+/- 2 days in either direction for each visit.  
• Assessments Administered (see section 4.1 for Abbreviations): 
 
Variable Interview 
Measure Self-Report 
Measure Task Measure 
Urine Pregnancy Screen 
(3rd visit only) - - x 
Blood Sample (10 ml tube) - - Serum E2/P4 
Suicidality Full SITBI - - 
Depression - CESD  - 
Hopelessness - BHI FT-IRAP 
Inhibitory Control - UPPS -P SST 
Threat Sensitivity - STAI DPT 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 31 
 Negative Social Appraisals - SSES  SAR-IAT 
Side Effects and 
Compliance Monitoring X - - 
 
DEBRIEFING VISIT – 30 MINUTES 
 
• Timing: Debriefing will occur within a 15 day window following completion of the 
second condition.  
• Individual results will not be reported to the patient.  
• Referral to original care provider will be facilitated as necessary.  
• Assessments Administered (see section 4.1 for Abbreviations): 
 
Variable Interview 
Measure Self-Report 
Measure Task Measure 
Final Suicide Risk 
Assessment Full SITBI - - 
 
7.1.[ADDRESS_1259679] OF CARE STUDY PROCEDURES  
 
Although the LRAP/UWRAP dictates the provision of basic supportive conversation an d other 
simple interventions to reduce imminent risk in the context of increased suicidality,  participants 
are expected to utilize their mental health provider for any treatment  needs that arise during the 
course of the study. Therefore, participation will require that the part icipant consents to phone 
contact [CONTACT_898840] [INVESTIGATOR_898789]: (1) one 
standard phone contact [CONTACT_898841] 
[INVESTIGATOR_898790]; and (2) as-needed phone contact [CONTACT_898842]. 
 
7.2 LABORATORY PROCEDURES/EVALUATIONS 
 
7.2.[ADDRESS_1259680]  will be completed in our laboratory on site on two 
occasions: prior to randomization at the enrollment visit, and at the third st udy visit of the first 
condition. 
 
At all 6 laboratory assessments during active treatment with placebo or E2/P4, women will 
provide 10ml blood samples  to be assayed for E2/P4 to evaluate the success of the hormone 
in achieving stable luteal phase levels of E2/P4. Cheryl Walker’s laboratory at UNC w ill conduct 
assays. Storage onsite will be handled by [CONTACT_898843] s in [CONTACT_898875]’s 
laboratory.  
 
7.2.[ADDRESS_1259681]. Girdler ’s lab. Standard freezer-proof labels will indicate participant 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259682]. Cheryl 
Walker’s laboratory in batches. Following assay, any additional serum will be stored in 
[CONTACT_898869]’s laboratory .  
 
7.2.4 SPECIMEN SHIPME NT 
 
Serum transport will be handled by [CONTACT_898844]’s Bioendocrine lab 
under dry ice conditions. Samples will be sent in batches when there are enough 
aliquots to support purchase of RIA kits.  
 
7.[ADDRESS_1259683] prior to the enrollment  visit; 
because all information about eligibility obtained during the phone screen is confirm ed at the 
enrollment visit, there is no expi[INVESTIGATOR_898791]. 
 
Women will be recruited primarily through chart review at the UNC outpat ient psychiatry clinic; 
only those women agreeing to be recontact[CONTACT_898845]. Dr . 
Eisenlohr-Moul will identify women via chart review who may be eligible for  the study, and 
contact [CONTACT_47252], and conduct phone screening in interested individuals.  
 
Following verbal consent, verbal phone screening will include verbal assessment of all 
inclusion/exclusion criteria described above, including assessment of recent suicidality usi ng the 
shortened SITBI.  
 
7.3.2 ENROLLMENT/BASELINE 
 
Following recruitment screening via telephone, interested individuals will schedul e and attend 
an enrollment visit at which they will provide informed consent and be further  assessed for 
eligibility; assessment for eligibility includes assessment of height and weight ( BMI), urine HcG 
pregnancy test, consent to contact [CONTACT_898846] i ntervals for study 
participation, and other self-reported inclusion/exclusion criteria (including ap propriate level of 
suicide risk on the SITBI -- see information in section 5.1). If ineligible, they will be referr ed back 
to their mental health provider and receive payment for the enrollment visit . If eligibility is 
confirmed, they will be further characterized using the SCID-I and S CID-II and complete various 
psychosocial questionnaires. In addition, they will be trained in the protocol fo r urine ovulation 
testing, daily telephone assessments, and the patch/pi[INVESTIGATOR_898792]. Par ticipants 
will be randomized to one of two possible condition orders at that time.  
 
Pregnancy test must be negative in order for the participant to continue wi th the study. The 
study agent will not be administered until Lab assessment 1 (i.e., not at ba seline/enrollment).  
 
7.3.3 FOLLOW- UP  
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 33 
 Following the baseline/enrollment visit, women will remain in contact [CONTACT_898847]. When ovulation testing is positive (day 0 ), 
the participant will contact [CONTACT_898848] (visits for condition 1) on days +7, +14, and +22. All laboratory 
assessment visits are identical in structure and content, with the singular exception that 
the third laboratory visit in the first condition will include a pregnancy test that must be  
negative prior to starting the second condition. When the first condition is complete d 
and the second pregnancy test is negative at the third laboratory visit, women wil l again 
remain in contact [CONTACT_898849]. Once again, when ovulation is confirmed (day 0), the final 3 laboratory 
assessments (for condition 2) will be scheduled on days +7, +14, and +22. These visits 
may be scheduled up to +/-2 days in either direction. 
 
• Follow-Up Assessments Administered (see section 4.1 for Abbreviations): 
 
Variable Interview 
Measure Self-Report 
Measure Task Measure 
Vitals - - Weight 
Urine Pregnancy Screen 
(3rd follow-up only) - - x 
Blood Sample (10 ml tube) - - Serum E2/P4 
Suicidality Full SITBI - - 
Depression - CESD  - 
Hopelessness - BHI FT-IRAP 
Inhibitory Control - UPPS -P SST 
Threat Sensitivity - STAI DPT 
Negative Social Appraisals - SSES  SAR-IAT 
Side Effects, AEs, and 
Compliance Monitoring X - - 
 
Follow-Up Timeline: 
 
Condition 1 (Follow-Up Visits 1-3):  
 
- Negative Pregnancy Test Confirmed at Enrollment 
- Ovulation Testing  
- Positive Ovulation Test #1= Day 0 
- Study Followup Visits 1-3 Scheduled for days +7, +14, +22 
- Study Followup Visit 1 (Day +7): Assessments, administration of stud y agent patch A and 
dispensation of pi[INVESTIGATOR_3353] (Condition 1)  
- Study Followup Visit 2 (Day +14) : Assessments, replacement of study agent patch A with 
patch B (Condition 1)  
- Removal of study patch and end of pi[INVESTIGATOR_519192] +21 
- Study Followup Visit 3 (Day +22): Assessments, Pregnancy Test 
 
Condition 2 (Follow-Up Visits 4-6):  
 
- Negative Pregnancy Test Confirmed at Visit 3 
- Ovulation Testing  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259684]= Day 0 
- Study Followup Visits 4-6 Scheduled for days +7, +14, +22 
- Study Followup Visit 4 (Day +7): Assessments, administration of study agent patch A and 
dispensation of pi[INVESTIGATOR_3353] (Condition 2)  
- Study Followup Visit 5 (Day +14): Assessments, replacement of study age nt patch A with 
patch B (Condition 2)  
- Removal of study patch and end of pi[INVESTIGATOR_519192] +21 
- Study Followup Visit 6 (Day +22): Assessments, Schedule Debriefing 
 
7.3.4 FINAL STUDY VISIT 
 
Debriefing visits will be scheduled within 15 days of study completion. In this final visit, a final 
risk assessment will be conducted and the participant will be referred as a ppropriate for 
additional clinical care. This final risk evaluation visit is included in order to reduce the likelihood 
of emergent risk following withdrawal from exogenous hormones in women who ha d the 
placebo-experimental condition order. Participants will not be provided with indiv idualized study 
results.  
 
7.3.5 EARLY TERMINATION VISIT 
 
Should early termination be deemed necessary (following procedures detailed above), an d the 
situation does not involve a need for immediate hospi[INVESTIGATOR_301978],  then the 
participant will be invited to an early termination visit in which the ful l typi[INVESTIGATOR_898793] 
(i.e., risk assessment and referral as appropriate) will be conducted.  
 
7.3.6 UNSCHEDULED VISIT 
 
There will be no unscheduled visits. Should a participant present at the laborator y at the wrong 
time, a member of the study staff will reschedule the visit if needed  or refer her to her mental 
health provider as appropriate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 35 
 7.3.7 SCHEDULE OF EVENTS TABLE  
Procedures 
Screening 
Enrollment/Baseline 
IDS RANDOMIZATION 
Follow-Up (Condition 1, Visit 1) 
Follow-Up (Condition 1, Visit 2) 
Follow-Up (Condition 1, Visit 3) 
Follow-Up (Condition 2, Visit 4) 
Follow-Up (Condition 2, Visit 5) 
Follow-Up (Condition 2, Visit 6) 
Final Visit/ Debriefing Visit 
Informed Consent Verbal 
x Written 
x         
Demographics x x         
Medical History/Inclusion/Exclusion Criteria x x         
SCID – Diagnostic Interview  x         
SITBI – Suicidality Interview  x x x x x x x x x 
Randomization   x        
Administer Study Agent E2 (or placebo) Patch    x x  x x   
Dispense Study Agent P4 (or placebo) Pi[INVESTIGATOR_3353]    x x  x x   
Height/Weight   x         
E2/P4 Serum Measure    x x x x x x  
CESD - Depression Self-Report    x x x x x x  
BHI – Hopelessness Self-Report    x x x x x x  
STAI – Anxiety/Threat Sensitivity Self-Report    x x x x x x  
SSES – Negative Social Appraisals Self-Report    x x x x x x  
UPPS- P – Impulsivity/Inhibitory Control Self-Report    x x x x x x  
FT-IRAP – Hopelessness Task    x x x x x x  
SAR-IAT – Negative Social Appraisal Task    x x x x x x  
SST – Inhibitory Control Task    x x x x x x  
DPT – Threat Sensitivity Task    x x x x x x  
Adverse Event/Side Effect Evaluation    x x x x x x  
 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES 
 
Placebo control is required to demonstrate unique effects (vs. expectancy ef fects) of hormones 
on indices of suicidality.  
 
Ongoing Assessment of Suicidality 
 
The PI ([CONTACT_704968]-Moul) is a clinical psychologist with seven years of  experience in risk 
assessment and empi[INVESTIGATOR_898794] (e.g.,  Dialectical Behavior 
Therapy); [CONTACT_898870], the consulting clinical psychologist, has over [ADDRESS_1259685] of which included structured intervi ews for the 
assessment of suicidality and other psychiatric symptoms. The available literature3 indicates 
that participants in research studies do not generally become acutely upset in response 
to the psychological assessments conducted in the present study.  If participants do 
become upset during an assessment, they will be reminded of their right to discon tinue 
participation, and mood changes or suicidality will be assessed and managed usi ng the 
University of Washington Risk Assessment and Management Procedure ( UWRAP ), the suicide 
risk management protocol recommended by [CONTACT_898850] .  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 36 
 7.5 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCED URES  
 
 
All concomitant prescription medications taken during study participation will be recorded. For 
this protocol, a prescription medication is defined as a medication that can be prescribed only  by 
a properly authorized/licensed clinician. Medications to be reported are concomitant  prescription 
medications, over-the-counter medications and non-prescription medications. 
 
 
7.5.1 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDU RES 
 
There are no medications that are prohibited for concomitant use with the study agen ts, with the 
exception of any hormonal preparations (that are exclusionary). 
 
7.6 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDU RES  
 
There are no prohibited medications or procedures except hormonal preparations, which are 
exclusionary.  
 
7.7 PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDU RES  
 
Not applicable. 
7.8 RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES  
 
Not Applicable.  
 
Hospi[INVESTIGATOR_898795] a “rescue treatment” should imminent suicidal risk emerge. 
 
7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSUR E  
 
Participants will not be provided access to study medications following the terminat ion of this 
study; as noted above, this is a mechanistic experimental study and not a treatm ent study. 
 
8 ASSESSMENT OF SAFETY 
 
The safety of the study and its participants (as described in 2.3.1) will be monitored v ia 
(1) Supervising clinicians David Rubinow, M.D. (hormone-related AEs) and Mitch 
Prinstein, Ph.D. (mood and suicide-related AEs) as well as (2) a Data and Safety 
Monitoring Board (DSMB).  
 
AEs will be assessed daily during the telephone contacts in the two administration 
conditions, and will be assessed weekly at laboratory visits. All AEs will be reported 
immediately to the PI [INVESTIGATOR_20196]. Girdler, who will determine severity and next steps in 
consultation with the appropriate clinical supervisor (Rubinow for physical adverse 
events, Prinstein for psychological and behavioral adverse events). 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 37 
  
The DSMB will evaluate AEs that are submitted during scheduled reviews. The North 
Carolina Translational and Clinical Sciences (NCTraCS) Data and Safety Monitoring 
Board (NCTraCS DSMB) has agreed to serve in this role. The Board is composed of 
MDs from a variety of disciplines, an R.N. from the UNC School of Nursing, a 
Biostatistician, a Regulatory Expert, and for purposes of this study, a psychiatrist o r 
clinical psychologist may serve as an ad hoc member.  
 
Although not expected given the doses and duration of hormone expo sure, the DSMB 
will, during scheduled reviews, specifically evaluate the frequency of AEs relat ed to the 
hormonal RCT. The DSMB will specify the tables and data it wishes to have presented 
to it at all meetings, including but not limited to, moderate to severe side effects and all 
serious adverse events. DSMB review of this study will occur every six months . At 
these meetings the DSMB will also review data from participants who have been 
discontinued by [CONTACT_898851], and t he 
reasons for discontinuation. The DSMB will also identify if any study procedures should 
be altered or stopped in the event of an indication of harm to participants  attributable to 
the study interventions. The DSMB will evaluate issues of participant safety as well as 
the adequacy and integrity of accumulating data, review of enrollment data, an d making 
recommendations regarding safety. 
 
8.1 SPECIFICATION OF SAFETY PARAMETERS 
 
8.1.1 DEFINITION OF ADVERSE EVENTS (AE) 
 
Adverse event  means any untoward medical occurrence associated with the use of an 
intervention inhumans, whether or not considered interventi on-related (21 CFR 312.32 (a)). 
 
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) 
 
Serious adverse event or serious suspected adverse reaction . An AE or suspected adverse 
reaction is considered "serious" if, in the view of either the investigator or  sponsor, it results i n 
any of the following outcomes: death, a life-threatening adverse event, inpatient hospi[INVESTIGATOR_898796], or a persistent or significant incap acity. Important 
medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_34502], based upon appropriate medical judgment, they may jeopardiz e 
the patient or subject and may require medical intervention to prevent one of the outcomes 
listed in this definition.  
 
*Notable examples of serious adverse events in the present study include development 
of a venous thromboembolism or suicide attempt.  
 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP) 
 
OHRP considers unanticipated problems involving risks to participants or other s to include, in 
general, any incident, experience, or outcome that meets all of the following criteria:  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 38 
 • Unexpected in terms of nature, severity, or frequency given (a) the research pr ocedures 
that are described in the protocol-related documents, such as the IRB-approved 
research protocol and informed consent document; and (b) the characteristics of t he 
participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” m eans 
there is a reasonable possibility that the incident, experience, or outcome may ha ve 
been caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm  
(including physical, psychological, economic, or social harm) than was previously k nown 
or recognized.  
 
This study will use the OHRP definition of UP. 
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT 
 
8.2.1 SEVERITY OF EVENT 
 
For AEs not included in the protocol defined grading system, the following g uidelines will be 
used to describe severity. 
 
• Mild – Events require minimal or no treatment and do not interfere with the p articipant’s 
daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity  and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life-threa tening or 
incapacitating. 
 
 
 
 
8.2.2 RELATIONSHIP TO STUDY AGENT 
 
For all AEs, Drs. Girdler and Eisenlohr-Moul will urgently collaborate with appropri ate clinical 
supervisors (Rubinow for physical/medical events, Prinstein for behavioral/psychological 
events) to determine the AE’s causality based on temporal relationship and his/her clinical 
judgment. The degree of certainty about causality will be graded using the cate gories below.  
Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event occurs in a plausible t ime 
relationship to drug administration and cannot be explained by [CONTACT_19009]. The response to withdrawal of the drug (dechallenge) should be cl inically 
plausible. The event must be pharmacologically or phenomenologically definitive, wi th use of a 
satisfactory rechallenge procedure if necessary.  
Probably Related – There is evidence to suggest a causal relationship, and the influence of 
other factors is unlikely. The clinical event occurs within a reasonable time af ter administration 
of the drug, is unlikely to be attributed to concurrent disease or other drugs or chemicals, and 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 39 
 follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge infor mation 
is not required to fulfill this definition.  
 
Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication) . However, other 
factors may have contributed to the event (e.g., the participant’s clinical condition, other 
concomitant events). Although an AE may rate only as “possibly related” soon after discov ery, it 
can be flagged as requiring more information and later be upgraded to “probabl y related” 
or“definitely related,” as appropriate.  
 
Unlikely to be related – A clinical event whose temporal relationship to drug administration 
makes a causal relationship improbable (e.g., theevent did not occur within a reasonable time 
after administration of the trial medication) and inwhich other drugs or chemicals or underlying 
disease provides plausible explanations (e.g., theparticipant’s clinical condition, other 
concomitant treatments). 
 
Not Related – The AE is completely independent of study drug administration, and/or 
evidenceexists that the event is definitely related to another etiology. The re must be an 
alternative, definitive etiology documented by [INVESTIGATOR_124]. Rubinow or [CONTACT_898870].  
 
 
8.2.3 EXPECTEDNESS  
 
Drs. Girdler and Eisenlohr-Moul will collaborate with appropriate clinical supervisors (Rub inow 
for physical/medical, Prinstein for psychological/behavioral) to make determ inations about 
whether an AE is expected or unexpected. An AE will be considered unexpected i f the nature, 
severity, or frequency of the event is not consistent with the risk information prev iously 
described for the study agent.  
 
8.[ADDRESS_1259686] emic reactions not 
meeting the criteria for SAEs will be captured on the appropriate documentatio n. Information 
to be collected includes event description, time of onset, clinician’s assessment of severity, 
relationship to study product (assessed only by [CONTACT_8703] 
a diagnosis), and time of resolution/stabilization of the event. All AEs occurr ing while on 
study must be documented appropriately regardless of relationship. All AEs wil l be followed 
to adequate resolution .  
 
Pre-existing medical conditions are exclusionary for participation in the trial,  with the 
exception of psychiatric conditions. Any psychiatric condition or symptom that is p resent at 
the time that the participant is screened, including mood symptoms and suici dal ideation , will 
be considered as baseline and not reported as an AE. However, if the study partici pant’s 
condition or symptom deteriorates significantly with regard to the severity or i mpact of the 
symptom on the participants functioning or safety (as determined by D rs. Eisenlohr-Moul, 
Girdler, Rubinow, and Prinstein) at any time during the study, it will be r ecorded as an AE. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259687] all reportable events with start dates occurring any time  after informed 
consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs ) after the last day of 
study participation. At each phone call and study visit, study staff wil l inquire about the 
occurrence of AE/SAEs since the last visit. All AEs will be immedia tely (within 2 hours) reported 
to the PI, who will consult with Drs. Girdler, Rubinow, and Prinstein in the  [ADDRESS_1259688] with experience in suicide risk assessment (Eisenlohr-Moul or 
Prinstein) using the LRAP/UWRAP protocol (the tool recommended by [CONTACT_898852]). Medical/physical AEs will be discussed as soon as 
possible, and within the following [ADDRESS_1259689]. Eisenlohr-Moul (in consultation with Drs. Girdler, Rubinow, and Prinstein) will 
review all protocol data at weekly meetings, including enrollment and retention statistics 
and aggregate reports of side effects/AEs. As the contact [CONTACT_976], [CONTACT_704968]-Moul will b e 
the one responsible for reporting any severe AEs to the IRB and DSMB within [ADDRESS_1259690] (i.e., a non-IND study), 
unexpected Serious AEs will be also be reported to the FDA Medwatch Program. The 
NIMH program officer will be notified of any study modifications or suspension imposed 
by [CONTACT_898853].  
 
 
8.4.2 SERIOUS ADVERSE EVENT REPORTING  
 
The PI ([CONTACT_704968]-Moul) will complete a SAE Form within the followi ng timelines:  
• All deaths and immediately life-threatening events, whether related or  unrelated, will be 
recorded on the SAE Form and submitted to the DCC/study sponsor withi n [ADDRESS_1259691] information.  
 
All SAEs will be followed until satisfactory resolution or until the  PI [INVESTIGATOR_340991]. Other supporting documentation of the event  may be 
requested by [CONTACT_898854]. The  study 
sponsor will be responsible for notifying FDA of any unexpected fatal or li fe-threatening 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 41 
 suspected adverse reaction as soon as possible but in no case later than 7 calendar days after 
the sponsor's initial receipt of the information. 
8.4.3 UNANTICIPATED PROBLEM REPORTING  
 
Incidents or events that meet the OHRP criteria for UPs require the crea tion and completion 
of an UP report form. It is the site investigator’s responsibility to r eport UPs to their IRB and 
to the study sponsor. The UP report will include the following information:   
• Protocol identifying information: protocol title and number, PI’s name, and t he IRB 
projectnumber; 
• A detailed description of the event, incident, experience, or outcome; 
• An explanation of the basis for determining that the event, incident, experience, or 
outcomerepresents an UP; 
• A description of any changes to the protocol or other corrective actions th at have been 
taken or are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported usi ng the following 
timeline:  
• All UPs will be reported to the IRB, the DSMB, and to the study sponsor wit hin [ADDRESS_1259692]. Rubinow; [CONTACT_187951] will oversee appropriate clinical care, including supervised 
hormonal discontinuation.  
 
8.5 STUDY HALTING RULES  
 
At six month intervals, the study biostatistician ([CONTACT_898874]) will test whe ther there are significant 
differences in the occurrence of moderate, severe, and serious AEs in the placebo vs. the  
experimental condition with alpha set at .05. These results will be provided t o DSMB along with 
the summary report of enrollment.  
 
Administration of study agent will be halted when three serious AEs* determined to be “probably 
related” are observed. The PI [INVESTIGATOR_898778]. The DSMB 
will notify the study sponsor and investigators immediately when the third severe event is 
reported and enrollment screens will stop accepting new study participants. [CONTACT_898874] will again 
perform an unblinded statistical analysis to further determine whether active study medication 
(E2/P4) is significantly related to greater risk of AEs relative to placebo. A ll requested 
documentation will be provided to the DSMB. The DSMB will convene an ad hoc meetin g by 
[CONTACT_145862]. The DSMB will provide recommendation s for 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259693]. Xia: specifically, if the experimental hormone stabilization conditi on is 
associated with greater risk of severe or serious AEs than placebo, and there is evidence (as 
determined by [INVESTIGATOR_187898]) that such AEs are causally related to the study drug, t he study 
will be terminated.  
 
*Notable examples of serious adverse events in the present study include development 
of a venous thromboembolism or suicide attempt.  
 
 
8.[ADDRESS_1259694] of the trial is in compliance with the currently approved protocol/amendment(s),  with 
GCP, and with applicable regulatory requirement(s).  
• Katherine McCann, the project manager, will be responsible for the adequate clinical 
documentation of all events as described in the current protocol, including data 
verification and backup.  
• Evaluation of the safety of the study will take place via the DSMB every six months and 
as needed when AEs emerge (see sections above).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259695] all analyses at the end of t he trial.  
 
10.2 STATISTICAL HYPOT HESES  
 
Hypotheses. For suicidal desire 
and suicidal action capacity —our 
primary endpoints (see far right side 
of figure in Figure at right) —we 
predict that perimenstrual increases 
in suicidal desire and action capacity 
(Lab 2 – Lab 1 within each condition) 
will be larger in the placebo 
condition than in the experimental 
hormone stabilization condition. The 
associated null hypothesis is that 
there will be no difference in the 
perimenstrual increase in suicidality 
across condition. For our secondary 
endpoints, including hopelessness, 
negative social appraisals, reduced 
inhibitory control, and threat 
sensitivity, we predict the same 
pattern of results.   
 
There are no “efficacy” endpoints in the present trial since it is mechanisti c and not a treatment 
study. 
 
10.[ADDRESS_1259696] using this intent- to-treat sample.  
 
10.4 DESCRIPTION OF STATISTICAL METHODS 
 
10.4.1 GENERAL APPROACH 
 
The design of this study is a two-period crossover design, where each of two study 
periods is a perimenstrual frame of the menstrual cycle (days +7 to +[ADDRESS_1259697] day=0). Each participant will complete both 
conditions in a randomized order.  
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 44 
 The primary windows of comparison will be the final seven days of each administratio n 
phase, which will allow for a compariso n of a woman’s mean scores in the placebo 
condition compared to her mean scores in the experimental condition. 
 
Primary hypothesis tests will be evaluated using a alpha level of .05, with a two-tailed  
test. 
 
All outcomes will be checked for normality; given the low likelihood that suicidality will 
follow a normal distribution even in this clinical sample, we expect that we will need to 
utilize nonparametric procedures.  
 
10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 
Primary and secondary endpoints are operationalized above (i.e., mean  within-person 
differences between placebo and experimental in final seven days of manipulation ) for 
the daily SITB suicidal ideation and planning subscales (primary endpoints) as well as 
the daily UPPS-P impulsivity, PROMIS anxiety, CESD depression, BHI hopelessness, 
and SSES rejection sensitivity subscales (secondary endpoints).  
 
Analyses will proceed identically for all outcomes listed above . First, we will 
calculate each subject’s mean daily rating (via phone) on the outcome measure in the 
final seven days  of both the placebo condition (placebo mean score) and the 
experimental condition (experimental mean score).  
 
Second, we will utilize paired samples t-tests to examine the within-person cond ition 
effect. If proposed covariates (medicines, BMI, age) show sufficient variability, we will 
instead use a repeated measures ANCOVA to evaluate the condition effect. These 
analyses will be conducted on the intent- to-treat dataset. 
 
If necessary due to violations of model assumptions, we will utilize similar 
nonparametric tests. 
 
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT( S) 
 
See above.  
 
10.4.[ADDRESS_1259698], calcu lated 
dichotomously based on its emergence during the treatment timeframe. These  
outcomes will be presented in tables for review by [CONTACT_4318], and such outcomes will 
be accompanied by [CONTACT_898855] (both mean levels and change 
from baseline in each condition) to determine whether AEs and changes in AEs are 
more likely to occur in the experimental condition.  
 
Below, we list the adverse events that are most likely to occur in the course of the  study 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259699] closely (at every daily and weekly participant  
contact [CONTACT_898856]). However, participants will have t he 
opportunity to report any other adverse event in addition to those listed below.  
 
GENERAL ADVERSE EVENTS 
 
• Significant deterioration in mood  
• Significant deterioration in suicidality 
• Any adverse event related to venipuncture 
• Any adverse event related to emotional or behavioral reactions to interviews, 
questionnaires, or tasks 
 
ESTRADIOL PHYSICAL SIDE EFFECT ADVERSE EVENTS  
 
The most frequent side effects associated with estradiol use include: 
- breast tenderness (occurs in 29% of patients) 
- abdominal cramps (occurs in 16% of patients) 
- headache (occurs in 13% of patients) 
- edema (swelling) (occurs in 10% of patients) 
- nausea (occurs in 6% of patients) 
- acne (occurs in 3 – 12% of patients) 
- skin rash or irritation may also occur at site where the patch is placed ( occurs in 3 - 12% of 
patients) 
 
Rare side effects (<1%) include: 
- jaundice (yellowing of skin) 
- increased blood pressure 
- worsening of migraines or asthma 
- enlargement of uterine fibroids 
- intolerance to contact [CONTACT_13276] 
- dizziness 
- changes in appetite and weight 
 
PROGESTERONE PHYSICAL SIDE EFFECT ADVERSE EVENTS 
 
The most common side effects associated with progesterone include: 
- breast tenderness (occurs in 16% of patients) 
- dizziness (occurs in 24% of patients) 
- abdominal crampi[INVESTIGATOR_007] (occurs in 20% of patients) 
- headache (occurs in 16% of patients) 
- viral infection (occurs in 12% of patients) 
- joint pain (occurs in 12% of patients) 
- diarrhea (occurs in 8% of patients) 
- menstrual bleeding, sometimes consistent with a heavy menstrual period (occurs i n 
20-30% of 
patients) 
- drowsiness (occurs in 9% of patients) 
 
Rare (<1%) side effects include: 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259700] pain 
- abdominal bloating  
 
10.4.5 ADHERENCE AND RETENTION ANALY SES  
 
Adherence to hormone administration protocols will be characterized following the close  
of the study using serum assays for E2 and P4 during the active condition relative to  
hormonal profiles during the placebo condition; it will not be monitored in real time.  
 
Women will be monitored in their compliance daily during each study condition v ia a 
phone call with study staff. Any deterioration in adherence will be immediately reme died 
via increased reminders and phone calls. 
 
10.4.6  BASELINE DESCRIPTIVE STATISTICS 
 
Groups (counterbalanced order as placebo-experimental or experimental-placebo) w ill 
be compared on demographic factors such as age, severity of perimenstrual mood  
change in the placebo condition, and general suicidality. However, inferential statistics 
are not necessary as our primary outcome modeling procedures will control for any 
baseline differences that exist.  
 
10.4.7 PLANNED INTERIM ANALYSES  
 
[IP_ADDRESS] SAFETY REVIEW 
 
At six month intervals, the study biostatistician ([CONTACT_898874]) will test whe ther there are significant 
differences in the occurrence of moderate, severe, and serious AEs in the placebo vs. the  
experimental condition with alpha set at .05. These results will be provided t o DSMB along with 
the summary report of enrollment.  
 
Administration of study agent will be halted when three serious AEs* determined to be “probably 
related” are observed. The PI [INVESTIGATOR_898778]. The  DSMB 
will notify the study sponsor and investigators immediately when the third severe  event is 
reported and enrollment screens will stop accepting new study participants. [CONTACT_898874] will again 
perform an unblinded statistical analysis to further determine whether active study medication 
(E2/P4) is significantly related to greater risk of AEs relative to placebo. A ll requested 
documentation will be provided to the DSMB. The DSMB will convene an ad hoc meetin g by 
[CONTACT_145862]. The DSMB will provide recommendation s for 
proceeding with the study to the PI [INVESTIGATOR_290665]. The study sponsor will inform  all appropriate 
regulatory agencies of the temporary halt and the disposition of the study . 
 
The DSMB will consider stoppi[INVESTIGATOR_898779]. Xia: specifically, if the experimental hormone stabilization conditi on is 
associated with greater risk of severe or serious AEs than placebo, and there is evidence (as 
determined by [CONTACT_898857]. Xia)  that 
such AEs are causally related to the study drug, the study will be terminat ed.  
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 47 
 *Notable examples of serious adverse events in the present study include development 
of a venous thromboembolism or suicide attempt.  
 
[IP_ADDRESS] EFFICACY REVI EW 
 
There are no efficacy endpoints in the present study because this is not a treatment 
study and the intervention used is not expected to be an effective treatment for an y 
condition. 
 
10.4.[ADDRESS_1259701] sub-group analyses, and therefore they will not be 
performed. 
 
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY 
 
N/A 
 
10.4. [ADDRESS_1259702] udy, 
with the goal of 30 women completing the study.  
 
Power analyses are described below; alpha is set at .05, power at 80%. The null 
hypothesis is no link between the study experimental condition and risk for suicida l 
ideation, intent, and planning; the alternate hypothesis is that hormone stabilizatio n in 
the experimental condition will prevent flux in these suicide-related outcomes. Be cause 
no previous studies have examined the impact of experimental hormones on suicid ality, 
we have conducted power analyses using existing effect sizes on related constructs 
(e.g., BPD features).  
 
Power Analysis . For the contrast testing the primary hypothesis, we will have power to det ect a 
conventionally medium-sized effect of hormone withdrawal ( r = .30; d = .60) at 80% power with 
just 17 participants165. The PI’s previous work in women with BPD suggests that attrition could be 
as high as 25% across two conditions; should attrition be this high, enrollmen t of 22 participants 
would be required for adequate power. However, to improve generalizability of ou r findings and 
to ensure 80% power to detect small- to-medium effect sizes ( r = .20; d = .40), we aim to include 
30 completers (with 45 women randomized). This number is especially reasonable gi ven the 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 48 
 much larger effects found in the candidate’s recent studies for the effect of natural ovarian steroid 
changes (average r = .58; d = 1.38) on daily symptoms of depression, rejection sensitivity, anxiety, 
and impulsivity40. 
 
10.6 MEASURES TO MINIMIZE BIAS 
 
10.6.1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURE S 
 
Individuals will be enrolled following phone screen and an enrollment visit as described above. 
Individuals will be randomized by [CONTACT_898858] (placebo-
experimental or experimental-placebo) following enrollment visit if they  meet study criteria and 
give informed consent. Masking and blinding will be handled by [CONTACT_898859], and will be fully double-blind. Randomization codes wil l be kept 
by [CONTACT_898860], and will be shared only as needed f or unblinding as 
needed for safety monitoring (described above).  
Blinding of Participants and Staff. All study staff performing assessments will remain blinded 
to condition.  The natural within-woman variation in menstrual cycle length from one cycle to 
another will help maintain the participant blind.  Few women have regular [ADDRESS_1259703] on women’s symptoms  (of note, 
this is scientifically accurate39). Finally, although it is possible that some women may become 
unblinded later in the extended hormone phase if they have extremely regular cycles , work by [CONTACT_898861]144. 
 
10.6.2 EVALUATION OF SUCCESS OF BLINDING  
 
At the conclusion of the study, each participant will be asked to guess which condition 
order they had. Blinding will be evaluated by [CONTACT_898862] 50% (chance).  
 
10.6.3 BREAKING THE STUDY BLIND/PARTICIPANT CODE 
 
Breaking of blind will occur to [CONTACT_187951] in the case of severe physical AEs (e.g., 
VTE) or hospi[INVESTIGATOR_059]/suicide attempt, and [CONTACT_898870] will also be unblinded if se vere 
AEs are related to suicidality.  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUM ENTS 
 
All data collected in this study will be maintained on the UNC protected servers and in 
clinical binders kept under lock and key in [CONTACT_898869]’s locked laboratory.  
 
12 QUALITY ASSURANCE AND QUALITY CONTROL 
 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 49 
 QC procedures will be implemented beginning with the data entry system and da ta QC checks 
that will be run on the database will be generated; this will be carried  out by [CONTACT_898863]. Any missing data or data anomalies will be communica ted to the 
PI [INVESTIGATOR_265824]/resolution.  
Following written SOPs, the monitors will verify that the clinical t rial is conducted and 
data are generated, documented (recorded), and reported in compliance with the 
protocol, GCP, and the applicable regulatory requirements (e.g., Good Laborato ry 
Practices (GLP), Good Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], an d 
inspection by [CONTACT_3482].  
 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
13.[ADDRESS_1259704]  
 
The investigator will ensure that this study is conducted in full conformity with Regulations for 
the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 
CFR Part 56, and/or the ICH E 6. 
 
13.[ADDRESS_1259705]  
 
The protocol, informed consent form(s), recruitment materials, and all part icipant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form must be obtained before any participant is enrolled. Any amendment to the protocol will 
require review and approval by [CONTACT_697843]. All 
changes to the consent form will be IRB approved; a determination wil l be made regarding 
whether previously consented participants need to be re-consented  
 
13.3 INFORMED CONSENT PRO CESS  
 
13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUM ENTS 
PROVIDED TO PARTICIPANTS 
 
Consent forms describing in detail the study agent, study procedures, and ri sks are given to the 
participant and written documentation of informed consent is required prior t o starting 
intervention/administering study product. The following consent materials are submit ted with this 
protocol including the adult informed consent and the consent for storage of specimens.  
 
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION 
 
Informed consent is a process that is initiated prior to the individual’s agreei ng to participate in 
the study and continues throughout the individual’s study participation. Exten sive discussion of 
risks and possible benefits of participation will be provided to the participants and t heir families. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259706] by [CONTACT_26573] i nvestigators, their staff, and 
the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical information relating to participants. There fore, the study 
protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any  
unauthorized third party. 
 
The study pa rticipant’s contact [CONTACT_65246]. At the end of the study, all records w ill continue to be kept in a 
secure location for as long a period as dictated by [CONTACT_515595].  
Study participant research data, which is for purposes of statistical analysis and s cientific 
reporting, will be transmitted to and stored on protected servers at UNC Ch apel Hill. Identifying 
information will be linked to ID number only in one password-protected file. I ndividual 
participants and their research data will otherwise be identified by a unique study i dentification 
number. The study data entry and study management systems used by [CONTACT_898864]. At the end of the study, all study databases will be  de-
identified and archived on UNC Chapel Hill servers. 
 
Certificate of Confidentiality 
To further protect the privacy of study participants, a Certificate of Confidentiality will be 
obtained from the NIH. This certificate protects identifiable research information f rom forced 
disclosure. It allows the investigator and others who have access to research records to re fuse 
to disclose identifying information on research participation in any civil, cri minal, administrative, 
legislative, or other proceeding, whether at the federal, state, or local lev el. By [CONTACT_898865], Certificates of Confidentiality help achieve the research obj ectives and 
promote participation in studies by [CONTACT_4205][INVESTIGATOR_21783] . 
 
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES,SPECIME NS OR DATA 
 
Study data include blood samples from laboratory visits and all psychosocial data  from 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 51 
 study participation.  
 
• Intended Use: Samples and data collected under this protocol may be used to study 
suicidality and psychiatric symptoms. No genetic testing will be performed.  
 
• Storage: Access to stored samples will be limited using locked access areas. Sampl es 
and data will be stored using codes assigned by [CONTACT_473]. Data will be kep t in 
password-protected computers. Only investigators will have access to the samples and 
data.  
 
• Tracking: Data will be tracked using password-protected files on the UNC s erver. 
Disposition at the completion of the study: All serum samples will be kept unde r locked 
access areas at UNC and on secure UNC servers. Study participants who request 
destruction of samples will be notified of compliance with such request and all  supporting 
details will be maintained for tracking. 
 
 
  
 
13.[ADDRESS_1259707]. Susan Girdler’s laboratory at 
UNC. After the study is completed, the de-identified, archived data will r emain in [CONTACT_898869]’s 
laboratory, under the supervision of medical technician Joe Hodges, for use by [CONTACT_72776]. Permission to retain samples in [CONTACT_898869]’s 
laboratory will be included in the informed consent.  
With t he participant’s approval and as approved by [CONTACT_898866] s, de -identified biological samples 
will be stored at the [CONTACT_898869]’s laboratory . These samples could be used for research into the 
causes of suicidality and other psychiatric symtpoms, and to improve treatment.  
 
During the conduct of the study, an individual participant can choose to withdr aw consent 
to have biological specimens stored for future research. However, withdrawal of consen t 
with regard to biosample storage will not be possible after the study is com pleted.  
The data and samples collected in this study will not be shared with other investigators . 
[ADDRESS_1259708] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIE S  
 
Data collection is the responsibility of the staff at the site under the supervision  of the PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and tim eliness 
of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. W hen making 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 52 
 changes or corrections, cross out the original entry with a single line, and init ial and date the 
change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE 
ORIGINAL.  
 
Copi[INVESTIGATOR_898797]. Data reported in the electronic data file 
derived from source documents should be consistent with the source documents or the 
discrepancies should be explained and captured in a progress note and maintained in the 
participant’s official electronic study record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reaction s data) 
and laboratory data will be entered into a local database on UNC servers . The data system 
includes password protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data wil l be entered 
directly from the source documents.  
 
14.2 STUDY RECORDS RETENTION  
 
Study documents will be retained for a minimum of 2 years following the en d of the study. These 
documents will be retained for a longer period, however, if required by [CONTACT_427]. No 
records will be destroyed without the written consent of the sponsor, if  applicable. It is the 
responsibility of the sponsor to inform the investigator when these documents no longer ne ed to 
be retained.  
 
14.3 PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MO P 
requirements. The noncompliance may be either on the part of the participan t, the investigator, 
or the study site staff. As a result of deviations, corrective actions are to be  developed by [CONTACT_91360]. 
 
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_1259709] be sent to the local IRB per their guidelines. The PI/study st aff is responsible for 
knowing and adhering to their IRB requirements.  
 
14.4 PUBLICATION AND DATA SHARING POLICY 
 
This study will comply with the NIH Public Access Policy, which ensures that the public has 
access to the published results of NIH funded research. It requires scientis ts to submit final 
peer-reviewed journal manuscripts that arise from NIH funds to the digital  archive PubMed 
Central upon acceptance for publication.  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 53 
 The International Committee of Medical Journal Editors (ICMJE) member j ournals have adopted 
a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial 
as any research project that prospectively assigns human subjects to intervention or concurr ent 
comparison or control groups to study the cause- and-effect relationship between a medical 
intervention and a health outcome. Medical interventions include drugs, surgical procedu res, 
devices, behavioral treatments, process- of-care changes, and the like. Health outcomes include 
any biomedical or health-related measures obtained in patients or participants, includi ng 
pharmacokinetic measures and adverse events. The ICMJE policy, and the Section [ADDRESS_1259710] of 2007, requires that all clinical trials be 
registered in a public trials registry , which is sponsored by [CONTACT_1055]. 
Other biomedical journals are considering adopting similar policies. For interv entional clinical 
trials performed under NIH IC grants and cooperative agreements, it is the grantee’s 
responsibility to register the trial in an acceptable registry, so the rese arch results may be 
considered for publication in ICMJE member journals. The ICMJE does not review spe cific 
studies to determine whether registration is necessary; instead, the committee   
recommends that researchers who have questions about the need to register err on the side of 
registration or consult the editorial office of the journal in which they wish to publi sh.  
FDAAA mandates that a "responsible party" (i.e., the sponsor or designated p rincipal 
investigator) register and report results of certain "applicable clinical trial s":  
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than  Phase I 
investigations, of a product subject to FDA regulation; 
 
The PI [INVESTIGATOR_898798] A. 
 
15 STUDY ADMINISTRATION 
 
15.1 STUDY LEADERSHIP 
 
The PI [INVESTIGATOR_898799] (Girdler, Prinstein, Rubinow, Young) will  govern the conduct of the 
study, along with NIMH program officer Mark Chavez. The PI [INVESTIGATOR_898800] K99 Career Development award on which this protocol is 
based.  
 
[ADDRESS_1259711].  
 
17  LITERATURE REFERENCES  
 
1. Joiner TEJ, Walker RL, Rudd MD, Jobes DA. Scientizing and routinizing t he 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 54 
 assessment of suicidality in outpatient practice. Professional Psychology: Research 
and Practice . 1999;30(5):447-453. doi:10.1037//0735-7028.30.5.447. 
2. Helms SW, Prinstein MJ. Risk assessment and decision making regarding 
imminent suicidality in pediatric settings. Clinical Practice in Pediatric Psychology. 
2014; 2(2):176-193. 
3. Linehan MM, Comtois KA, Ward-Ciesielski EF. Assessing and Managing Risk Wit h 
Suicidal Individuals. Cognitive and Behavioral Practice . 2012;19(2):218-232. 
doi:10.1016/j.cbpra.2010.11.008. 
4. Stricker R, Eberhart R, Chevailler M-C, Quinn FA, Bischof P, St ricker RE. 
Establishment of detailed reference values for luteinizing hormone, follicle 
stimulating hormone, estradiol, and progesterone during different phases of the  
menstrual cycle on the Abbott ARCHITECT analyzer. Clinical chemistry and 
laboratory medicine : CCLM / FESCC . 2006;44(7):883-887. 
doi:10.1515/CCLM.2006.160. 
5. Pearson JL, Claassen CA, Booth CL. Introduction to the suicide prevention 
research prioritization task force special supplement. Am J Prev Med . 2014. 
6. Nock MK, Kessler RC. Risk factors for suicide ideation differ from those for  the 
transition to suicide attempt: The importance of creativity, rigo r, and urgency in 
suicide research. Clinical Psychology: Science and Practice. 2016. 
doi:10.1111/cpsp.[ZIP_CODE]/pdf. 
7. Martel MM, Eisenlohr-Moul TA, Roberts B. Ovarian steroid dynamics and al cohol 
use: Effects of interactive levels, estradiol surges, and progesterone withdrawal . 
Under review. 
8. Eisenlohr-Moul TA, DeWall CN, Girdler SS, Segerstrom SC. Ov arian hormones and 
borderline personality disorder features: Preliminary evidence for interacti ve effects 
of estradiol and progesterone. Biological Psychology . 2015;109:37-52. 
doi:10.1016/j.biopsycho.2015.03.016. 
9. Eisenlohr-Moul TA, Walsh EC, Charnigo RJ, Lynam DR, Baer RA. The "What" and 
the “How” of Dispositional Mindfulness: Using Interactions Among Subscales of the 
Five-Facet Mindfulness Questionnaire to Understand Its Relation to Substance 
Use. 2012;19:276- 286. 
10. Derefinko KJ, Peters JR, Eisenlohr-Moul TA, Walsh EC, Adams ZW, Lynam  DR. 
Relations between trait impulsivity, behavioral impulsivity, physiological arousal, 
and risky sexual behavior among young men. Arch Sex Behav . 2014;43(6):1149-
1158. doi:10.1007/s10508- 014-0327 -x. 
11. Kniffin TC, Carlson CR, Ellzey A, et al. Using virtual reality t o explore self-regulation 
in high-risk settings. Trauma, Violence & Abuse . 2014;15(4):310-321. 
doi:10.1177/1524838014521501. 
12. Peters JR, Eisenlohr-Moul TA, Upton BT. Nonjudgment as a moderator of the 
relationship between present-centered awareness and borderline features: 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 55 
 Synergistic interactions in mindfulness assessment. Personality and Individual 
Differences. 2013 . 
13. Peters JR, Eisenlohr-Moul TA, Smart LM. Dispositional mindfulness and r ejection 
sensitivity: The critical role of nonjudgment. Personality and Individual Differences. 
2015.  
14. Peters JR, Smart LM, Eisenlohr-Moul TA, Geiger PJ, Smith GT, Bae r RA. Anger 
Rumination as a Mediator of the Relationship Between Mindfulness and 
Aggression: The Utility of a Multidimensional Mindfulness Model. J Clin Psychol . 
2015;71(9):871-884. doi:10.1002/jclp.[ADDRESS_1259712] lower aggressiveness via anger rumination: A multilevel mediation analysis. 
Mindfulness . In Press. 
16. Eisenlohr-Moul TA, Peters JR, Chamberlain KD, Rodriguez MA. Weekly  
Fluctuations in Nonjudging Predict Borderline Personality Disorder Feature 
Expression in Women. J Psychopathol Behav Assess . In Press . 
doi:10.1007/s10862- 015-9505 -y. 
17. DeWall CN, Pond R, Eisenlohr-Moul T. When opposites attack: Using I3  Theory to 
prospectively explore the role of disparate levels of self-control on intimate partner 
aggression.  In Press. 
18. Peters JR, Smart LM, Eisenlohr-Moul TA. Mindfulness and Rejection Sensi tivity: 
The central role of nonjudgment. Personality and Individual Differences. In Press. 
19. Peters JR, Eisenlohr-Moul TA, Pond RS, DeWall CN. The downside of  being 
sexually restricted: The effects of sociosexual orientation on relationships between 
jealousy, rejection, and anger. Journal of Research in Personality . 2014;51:18-22. 
20. Flynn S, Eisenlohr-Moul T, Segerstrom SC, Studts J. Shame, guilt, and knowledge 
of high prevalence rate of HPV among women recently diagnosed with cervical 
intraepi[INVESTIGATOR_28601] (CIN). Under review. 
21. Boggero IA, Eisenlohr-Moul TE. Task ‐switching ability protects against the adverse 
effects of pain on health: A longitudinal study of older adults. British journal of 
health psychology. In Press.  
22. Segerstrom SC, Eisenlohr-Moul TA, Evans DR, Ram N. Repetitive thought 
dimensions, psychological well-being, and perceived growth in older adults: a 
multilevel, prospective study. Anxiety, Stress, & Copi[INVESTIGATOR_007] . 2015;28(3):287-302. 
doi:10.1080/10615806.2014.947285. 
23. Eisenlohr-Moul TA, Burris JL, Evans DR. Pain acceptance, psychological 
functioning, and self-regulatory fatigue in temporomandibular disorder. Health 
Psychology . 2013. 
24. Greeson J, Eisenlohr-Moul T. Mindfulness-based stress reduction for chronic pain. 
Chapter in Press.  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.[ADDRESS_1259713] Soc Psychol . 2014;44(1):23- 30. 
26. Eisenlohr-Moul T, Segerstrom S. Autonomy, positive relationships, and IL -6: 
evidence for gender-specific effects. British Journal of Health Psychology . 
2013;18(2):420-438. doi:10.1111/j.2044-8287.2012.[ZIP_CODE].x. 
27. Eisenlohr-Moul TA, Crofford LJ, Howard TW, Yepes JF, Carlson CR, de Leeuw R . 
Parasympathetic reactivity in fibromyalgia and temporomandibular disorder: 
associations with sleep problems, symptom severity, and functional impairment. 
The journal of pain . 2015;16(3):247-257. doi:10.1016/j.jpain.2014.12.005. 
28. Eisenlohr- Moul TA, Fillmore MT, Segerstrom SC. “ Pause and plan” includes the 
liver: Self-regulatory effort slows alcohol metabolism for those low in self-cont rol. 
Biological Psychology . 2012;91(2):229-2 31. 
29. Baer RA, Peters JR, Eisenlohr-Moul TA, Geiger PJ, Sauer SE. Emot ion-related 
cognitive processes in borderline personality disorder: A review of the empi[INVESTIGATOR_898801]. Clinical Psychology Review . 2012;32(5):359-369. 
doi:10.1016/j.cpr.2012.03.002. 
30. Eisenlohr-Moul TA, Peters JR, Baer RA. Using mindfulness effectively  in clinical 
practice: two case studies. In: Case Studies in Psychotherapy . In Press . 
31. Duke AA, B e gue L, Bell R, Eisenlohr-Moul T. Revisiting the serot onin-aggression 
relation in humans: a meta-analysis. Psychological Bulletin . 2013;139(5):1148-
1172. doi:10.1037/a0031544. 
32. Segerstrom SC, Smith TW, Eisenlohr-Moul TA. Positive psychophysiology: T he 
body and self-regulation. In: Designing Positive Psychology: Taking Stock and 
Moving Forward. ; 2011:25- 40. 
33. Fang C, Eisenlohr-Moul TA, Rosenthal MZ. Biological correlates of personali ty 
disorder: a theoretical and empi[INVESTIGATOR_215103]. Biology of Mood & Anxiety Disorders . 
In Press . 
34. Eisenlohr-Moul TA, Owens S. Hormonal Influences in Cognitive, Affective, an d 
Behavioral Processes Relevant to Personality: A Review of Experimental and 
Longitudinal Work. In: Encyclopedia of Personality and Individual Differences . In 
Press. 
35. Eisenlohr-Moul TA, Peters JR, Derefinko KJ, Walsh E. When Does Neuroticism  
Predict Impulsivity? Evidence for the Sympathetic Nervous System as a Pred ictor of 
the Link Between Neuroticism and Negative Urgency. Drug and Alcohol 
Dependence . Under review. 
36. Derefinko K, Eisenlohr-Moul T, Peters J, Roberts W, Lynam D. Physiolog ical 
Response to Reward and Extinction Predicts Alcohol, Marijuana, and Cigarette Use 
Two Years Later. Drug and Alcohol Dependence . In Press. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 57 
 37. Eisenlohr-Moul T, Peters JR, Baer RA. How Do Mindfulness-Based Interv entions 
Work? Strategies for Studying Mechanisms of Change in Clinical Research. In: 
Handbook of Mindfulness and Self-Regulation . [LOCATION_001], NY: Springer [LOCATION_001]; 
2015:155-170. 
38. Mendle J, Keisner J, Eisenlohr-Moul TA. From M enarche to Menopause: Women’s 
Reproductive Milestones and Risk for Psychopathology: An Introduction to the 
Special Series. Clinical Psychological Science . In Press. 
39. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Different ial 
behavioral effects of gonadal steroids in women with and in those without 
premenstrual syndrome. The New England journal of medicine . 1998;338(4):209-
216. 
40. Eisenlohr-Moul TA, Rubinow DR, Schiller CE, Girdler SS. Histories o f abuse predict 
stronger within-person covariation of ovarian steroids and mood symptoms in 
women with menstrually related mood disorder. Psychoneuroendocrinology. In 
Press . 
41. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Girdler SS. Estradiol varia bility, 
stressful life events, and the emergence of depressive symptomatology during the 
menopausal transition. Menopause . In Press . 
42. Gordon J, Eisenlohr-Moul TA, Rubinow DR, Girdler SS. Naturally occurri ng 
changes in estradiol concentrations in the menopause transition predict morning 
cortisol and negative mood in perimenopausal depression. Clinical Psychological 
Science . In Press. 
43. Eisenlohr-Moul TA, Girdler SS, Dawson D, et al. Toward the Reliable Diag nosis of 
DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment 
Scoring System (C-PASS). Revisions Under Review. 
44. Keisner J, Mendle J, Eisenlohr-Moul TA. Examining Symptom Covariation Across 
the Menstrual Cycle Using Structural Equation Modeling of Cosine Amplitud es. 
Clinical Psychological Science . In Press. 
45. Walsh E, Eisenlohr-Moul T, Baer RA. Effects of a short mindful ness-based 
intervention on IL-6 and TNF-alpha in depressed women. Journal of consulting and 
clinical psychology.  In Press. 
46. Sauer-Zavala SE, Walsh EC, Eisenlohr-Moul TA, Lykins ELB. Comparing 
Mindfulness-Based Intervention Strategies: Differential Effects of Sitting Meditation, 
Body Scan, and Mindful Yoga. Mindfulness . 2012;4(4):383-388. 
doi:10.1007/s12671- 012-0139 -9. 
47. de Leeuw R, Eisenlohr-Moul T, Bertrand P. The association of smoking status with 
sleep disturbance, psychological functioning, and pain severity in patients with 
temporomandibular disorders. J Orofac Pain . 2013;27(1):32- 41. 
48. Segerstrom SC, Evans DR, Eisenlohr-Moul TA. Optimism and pessimism 
dimensions in the Life Orientation Test-Revised: Method and meaning. Journal of 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 58 
 Research in Personality . 2011;45(1):126-129. doi:10.1016/j.jrp.2010.11.007. 
49. Prinstein MJ. The Portable Mentor: Expert Guide to a Successful Career in 
Psychology . Springer Science & Business Media; 2012. 
50. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of 
gonadal steroids in women with a history of postpartum depression. American 
Journal of Psychiatry . 2000;157(6):924- 930. 
51. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of Estradiol Wi thdrawal on Mood 
in Women With Past Perimenopausal Depression: A Randomized Clinical Trial. 
JAMA psychiatry . 2015;72(7):714. doi:10.1001/jamapsychiatry.2015.0111. 
52. Bauer DJ, Preacher KJ, Gil KM. Conceptualizing and testing random indi rect effects 
and moderated mediation in multilevel models: New procedures and 
recommendations.  Psychological methods . 2006 Jun;11(2):142. 
53. Preacher KJ, Curran PJ, Bauer DJ. Computational Tools for Probing Interaction s in 
Multiple Linear Regression, Multilevel Modeling, and Latent Curve Analysis. Journal 
of Educational and Behavioral Statistics . 2006;31(4):437-448. 
doi:10.3102/1076998603100443 7. 
54. Baca-Garcia E. Association Between the Menses and Suicide Attempts: A 
Replication Study. Psychosomatic Medicine . 2003;65(2):237-244. 
doi:10.1097/01.PSY.[PHONE_18658].[ZIP_CODE].F6. 
55. Baca-Garcia E, Diaz-Sastre C, Ceverino A, et al. Suicide attempts among women 
during low estradiol/low progesterone states. Journal of Psychiatric Research . 
2010;44(4):209-214. doi:10.1016/j.jpsychires.2009.08.004. 
56. Baca-Garcia E, Díaz-Sastre C, de Leon J. The relationship between menstrual 
cycle phases and suicide attempts . Psychosomatic medicine. 2000 Jan 1;62(1):50-
60. 
57. Leenaars AA, Dogra TD, Girdhar S, Dattagupta S, Leenaars L. Men struation and 
Suicide. Crisis: The Journal of Crisis Intervention and Suicide Prevention . 
2009;30(4):202-207. doi:10.1027/0227-5910.30.4.202. 
58. Grimm S, Boesiger P, Beck J, et al. Altered negative BOLD responses in the  
default-mode network during emotion processing in depressed subjects. 
Neuropsychopharmacology . 2009;34(4):932-943. doi:10.1038/npp.2008.81. 
59. Beck AT, Brown G, Berchick RJ, Stewart BL, Steer RA. Relationship Between 
Hopelessness and Ultimate Suicide: A Replication With Psychiatric Outpatients. 
Focus . 2006;4(2):291-296. doi:10.1176/foc.4.2.291. 
60. Jollant F, Lawrence NL, Olié E, Guillaume SEB, Courtet P. The suicidal mind an d 
brain: A review of neuropsychological and neuroimaging studies. World Journal of 
Biological Psychiatry . 2011;12(5):319-339. doi:10.3109/15622975.2011.556200. 
61. Van Orden KA, Witte TK, Gordon KH, Bender TW, Joiner TE. Suicidal de sire and 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 59 
 the capability for suicide: tests of the interpersonal-psychological theory of suicidal 
behavior among adults. Journal of Consulting and Clinical Psychology . 
2008;76(1):72-83. doi:10.1037/0022-006X.76.1.72. 
62. Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and 
attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology . 
2001;24(5):467-477. doi:10.1016/S0893-133X(00)[ZIP_CODE]- 1. 
63. Venables NC, Sellbom M, Sourander A, et al. Separate and interactive 
contributions of weak inhibitory control and threat sensitivity to predi ction of suicide 
risk. Psychiatry Research . 2015;226(2-3):461-466. 
doi:10.1016/j.psychres.2015.01.018. 
64. Mann JJ, Arango VA, Avenevoli S, et al. Candidate endophenotypes for genetic 
studies of suicidal behavior. Biological Psychiatry . 2009;65(7):556-563. 
doi:10.1016/j.biopsych.2008.11.021. 
65. Gallo MA, Smith SS. Progesterone withdrawal decreases latency to and increases 
duration of electrified prod burial: a possible rat model of PMS anxiety. 
Pharmacology, Biochemistry and Behavior . 1993;46(4):897-904. 
66. Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the 
mouse results in anxiogenic effects of 3α,5β -THP: a possible model of 
premenstrual dysphoric disorder. Psychopharmacology . 2005;186(3):323-333. 
doi:10.1007/s00213- 005-0168 -3. 
67. Li Y, Pehrson AL, Budac DP, S a nchez C, Gulinello M. A rodent model of 
premenstrual dysphoria: progesterone withdrawal induces depression-like behavior 
that is differentially sensitive to classes of antidepressants. Behavioural Brain 
Research . 2012;234(2):238-247. doi:10.1016/j.bbr.2012.06.034. 
68. Hawton K, Van Heeringen K. Suicide. Lancet . 2009;373:1372- 1381.  
69. CDC Fatal Injury Report. 2013. 
70. Hawton K, Van Heeringen K. The International Handbook of Suicide and Attempted 
Suicide . 2000. 
71. Saunders K, Hawton K. Suicidal behaviour and the menstrual cycle. Psychol Med . 
2006;36(07):901. doi:10.1017/S0033291706007392. 
72. Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the 
mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of 
premenstrual dysphoric disorder. Psychopharmacology . 2006;186(3):323-333. 
doi:10.1007/s00213- 005-0168 -3. 
73. McEwen B. Estrogen actions throughout the brain. Recent progress in hormone 
research . 2002;57:357-384. 
74. Singh M, Su C, Ng S. Non-genomic mechanisms of progesterone action in the  
brain. Front Neurosci . 2013;7:159. doi:10.3389/fnins.2013.[ZIP_CODE]. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 60 
 75. Van Orden KA, Witte TK, Cukrowicz KC, Braithwaite SR, Selby [CONTACT_33684], Joiner TE. The 
interpersonal theory of suicide. Psychological Review . 2010;117(2):575-600. 
doi:10.1037/a0018697. 
76. Joiner TE, Van Orden KA, Witte TK, et al. Main predictions of the interpersonal-
psychological theory of suicidal behavior: empi[INVESTIGATOR_898802]. Journal of Abnormal Psychology . 2009;118(3):634-646. 
doi:10.1037/a0016500. 
77. Bender TW, Gordon KH, Bresin K, Joiner TE. Impulsivity and suicidality: t he 
mediating role of painful and provocative experiences. Journal of Affective 
Disorders . 2011;129(1-3):301-307. doi:10.1016/j.jad.2010.07.023. 
78. Hopelessness and eventual suicide: a 10-year prospective study of patients 
hospi[INVESTIGATOR_313303]. American Journal of Psychiatry . 
1985;142(5):559- 563. 
79. Joiner TE, Brown JS, Wingate LR. The psychology and neurobiology of suicidal 
behavior. Annu Rev Psychol . 2005;56(1):287-314. 
doi:10.1146/annurev.psych.56.091103.070320. 
80. Beckes L, Coan JA. Social Baseline Theory: The Role of Social Proximity in 
Emotion and Economy of Action. Social Pers Psych Compass . 2011;5(12):976-988. 
doi:10.1111/j.1751-9004.2011.[ZIP_CODE].x. 
81. Eisenberger NI, Lieberman MD, Williams KD. Does rejection hurt? An FMRI  study 
of social exclusion. Science . 2003;302(5643):290-292. 
doi:10.1126/science.1089134. 
82. DeWall CN, MacDonald G, Webster GD, et al. Acetaminophen Reduces Social 
Pain: Behavioral and Neural Evidence. Psychological Science . 2010;21(7):931-937. 
doi:10.1177/0956797610374741. 
83. Rich CL, Ricketts JE, Fowler RC, Young D. Some differences between men and 
women who commit suicide. American Journal of Psychiatry . 1988;145(6):718- 722. 
84. Moscicki EK. Epi[INVESTIGATOR_898803]: toward a 
framework for prevention. Clinical Neuroscience Research . 2001;1(5):310- 323. 
doi:10.1016/S1566-2772(01)[ZIP_CODE]- 9. 
85. Frye CA, Paris JJ, Rhodes ME. Estrogen is necessary for 5alpha-pregnan-3alpha-
ol-20-one (3alpha,5alpha-THP) infusion to the ventral tegmental area to faci litate 
social and sexual, but neither exploratory nor affective behavior of ovariectomized 
rats. Pharmacology, Biochemistry and Behavior . 2008;91(2):261-270. 
doi:10.1016/j.pbb.2008.08.018. 
86. Choleris E, Clipperton-Allen AE, Phan A, Valsecchi P, Kavaliers M. Estrogenic 
involvement in social learning, social recognition and pathogen avoidance. Frontiers 
in Neuroendocrinology . 2012;33(2):140-159. doi:10.1016/j.yfrne.2012.02.001. 
87. Frye CA. Neurosteroids' effects and mechanisms for social, cognitive, emotional, 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 61 
 and physical functions. Psychoneuroendocrinology . 2009;[ADDRESS_1259714] 1:S143-S161. 
doi:10.1016/j.psyneuen.2009.07.005. 
88. Schultheiss OC. The Hormonal Correlates of Implicit Motives. Social Pers Psych 
Compass . 2013;7(1):52-65. doi:10.1111/spc3.[ZIP_CODE]. 
89. Maner JK, Miller SL. Hormones and social monitoring: Menstrual cycle shifts in 
progesterone underlie women's sensitivity to social information. Evolution and 
Human Behavior . 2014;35(1):9-16. doi:10.1016/j.evolhumbehav.2013.09.001. 
90. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for l ifetime 
suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry . 
1999;56(7):617- 626. 
91. Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of the associations 
among mental disorders and suicidal behavior: findings from the WHO World 
Mental Health Surveys. Jenkins R, ed. PLoS medicine . 2009;6(8):e1000123. 
doi:10.1371/journal.pmed.1000123. 
92. Courtet P, Gottesman II, Jollant F, Gould TD. The neuroscience of suicidal 
behaviors: what can we expect from endophenotype strategies? Translational 
psychiatry . 2011;1(5):e7. doi:10.1038/tp.2011.6. 
93. Asberg M, Tr a skman L, Thor e n P. 5-HIAA in the cerebrospi[INVESTIGATOR_872]. A  
biochemical suicide predictor? Arch Gen Psychiatry . 1976;33(10):1193-1197. 
94. Mann JJ, Malone KM, Sweeney JA, et al. Attempted suicide characteristics and 
cerebrospi[INVESTIGATOR_898804]. 
Neuropsychopharmacology . 1996;15(6):576-586. doi:10.1016/S0893-
133X(96)[ZIP_CODE]- 9. 
95. Kamali M, Oquendo MA, Mann JJ. Understanding the neurobiology of suicidal 
behavior. Depress Anxiety . 2001;14(3):164-176. 
96. Oquendo MA, Placidi GPA, Malone KM, et al. Positron emission tomography of 
regional brain metabolic responses to a serotonergic challenge and lethality of 
suicide attempts in major depression. Arch Gen Psychiatry . 2003;60(1):14- 22. 
97. Du L, Merali Z, Poulter MO, Palkovits MOS, Faludi GAB, Anisman H. C atechol-O-
methyltransferase Val158Met polymorphism and altered COMT gene expression in 
the prefrontal cortex of suicide brains. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry . 2014;50:178-183. doi:10.1016/j.pnpbp.2013.12.016. 
98. Lord T, Taylor K. Monthly fluctuation in task concentration in female coll ege 
students. Perceptual and Motor Skills . 1991;72(2):435-439. 
doi:10.2466/pms.1991.72.2.435. 
99. Pastor AD, Evans SM. Alcohol outcome expectancies and risk for alcohol use 
problems in women with and without a family history of alcoholism. Drug and 
Alcohol Dependence . 2003;70(2):201- 214. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 62 
 100. Protopopescu X, Pan H, Altemus M, et al. Orbitofrontal cortex activity relat ed to 
emotional processing changes across the menstrual cycle. Proceedings of the 
National Academy of Sciences of the [LOCATION_002] of America . 
2005;102(44):[ZIP_CODE]-[ZIP_CODE]. doi:10.1073/pnas.[PHONE_18659]. 
101. Amin Z, Epperson CN, Constable RT, Canli T. Effects of estrogen variation on 
neural correlates of emotional response inhibition. NeuroImage . 2006;32(1):457-
464. doi:10.1016/j.neuroimage.2006.03.013. 
102. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal 
cognitive processes: a randomized, double-blind, placebo-controlled study with 
functional magnetic resonance imaging in perimenopausal and recently 
postmenopausal women. Menopause ([LOCATION_001], NY) . 2015;13(3):411-422. 
doi:10.1097/01.gme.[PHONE_18660].[ZIP_CODE].7b. 
103. Dumas JA, Kutz AM, Naylor MR, Johnson JV, Newhouse PA. Increased memory 
load-related frontal activation after estradiol treatment in postmenopausal women. 
Hormones and Behavior . 2010;58(5):929-935. doi:10.1016/j.yhbeh.2010.09.003. 
104. Jacobs E, D'Esposito M. Estrogen shapes dopamine- dependent cognitive 
processes: implications for women's health. The Journal of neuroscience . 
2011;31(14):5286-5293. doi:10.1523/JNEUROSCI.6394-10.2011. 
105. Löfgren M, Johansson I-M, Meyerson B, Lundgren P, B a ckstr o m TOR. 
Progesterone withdrawal effects in the open field test can be predicted by [CONTACT_898867]. Hormones and Behavior . 2006;50(2):208-215. 
doi:10.1016/j.yhbeh.2006.03.002. 
106. Löfgren M, Johansson I-M, Meyerson B, Turkmen S, B a ckstr o m TOR. 
Withdrawal effects from progesterone and estradiol relate to individual risk-tak ing 
and explorative behavior in female rats. Physiology & Behavior . 2009;96(1):91-97. 
doi:10.1016/j.physbeh.2008.08.015. 
107. Khan FA, Anand B, Devi MG, Murthy KK. Psychological autopsy of suicide-a cr oss-
sectional study. Indian journal of psychiatry . 2005;47(2):73-78. doi:10.4103/0019-
5545.[ZIP_CODE]. 
108. Giletta M, Calhoun CD, Hastings PD, Rudolph KD, Nock MK, Prinstein MJ. Multi-
Level Risk Factors for Suicidal Ideation Among at-Risk Adolescent Females: The 
Role of Hypothalamic-Pi[INVESTIGATOR_2117]-Adrenal Axis Responses to Stress. J Abnorm Child 
Psychol . 2014;43(5):807-820. doi:10.1007/s10802- 014-9897 -2. 
109. Gulinello M, Orman R, Smith SS. Sex differences in anxiety, sensorimotor gat ing 
and expression of the alpha4 subunit of the GABAA receptor in the amygdala after  
progesterone withdrawal. The European journal of neuroscience . 2003;17(3):641-
648. 
110. Devall AJ, Santos JM, Lovick TA. Estrous cycle stage influences on neurona l 
responsiveness to repeated anxiogenic stress in female rats. Behavioural Brain 
Research . 2011;225(1):334-340. doi:10.1016/j.bbr.2011.07.038. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 63 
 111. Isgor C, Huang GC, Akil H, Watson SJ. Correlation of estrogen beta-receptor 
messenger RNA with endogenous levels of plasma estradiol and progesterone in 
the female rat hypothalamus, the bed nucleus of stria terminalis and the medial 
amygdala. Brain research Molecular brain research . 2002;106(1-2):30-41. 
112. Toufexis D. Region- and sex-specific modulation of anxiety behaviours in the rat. J 
Neuroendocrinol . 2007;19(6):461-473. doi:10.1111/j.1365-2826.2007.[ZIP_CODE].x. 
113. Lovick TA. Estrous cycle and stress: influence of progesterone on the female br ain. 
Brazilian journal of medical and biological research. 2012;45(4):314- 320. 
114. Lovick TA, Devall AJ. Progesterone withdrawal-evoked plasticity of neural function 
in the female periaqueductal grey matter. Neural plasticity . 2009;2009(3):730902-
730908. doi:10.1155/2009/730902. 
115. Follesa P, Concas A, Porcu P, et al. Role of allopregnanolone in regulati on of 
GABA(A) receptor plasticity during long-term exposure to and withdrawal from  
progesterone. Brain research Brain research reviews . 2001;37(1-3):81-90. 
116. Griffiths J, Lovick T. Withdrawal from progesterone increases expression of alpha4 , 
beta1, and delta GABA(A) receptor subunits in neurons in the periaqueductal gray 
matter in female Wistar rats. The Journal of comparative neurology . 
2005;486(1):89-97. doi:10.1002/cne.[ZIP_CODE]. 
117. Griffiths JL, Lovick TA. GABAergic neurones in the rat periaqueductal grey  matter 
express alpha4, beta1 and delta GABAA receptor subunits: plasticity of expression 
during the estrous cycle. NSC . 2005;136(2):457-466. 
doi:10.1016/j.neuroscience.2005.08.013. 
118. Maguire J, Mody I. Steroid hormone fluctuations and GABA(A)R plasticity. 
Psychoneuroendocrinology . 2009;[ADDRESS_1259715] 1:S84-S90. 
doi:10.1016/j.psyneuen.2009.06.019. 
119. MacKenzie G, Maguire J. Chronic stress shifts the GABA reversal potential in the 
hippocampus and increases seizure susceptibility. Epi[INVESTIGATOR_138182] . 2015;109:13-
27. doi:10.1016/j.eplepsyres.2014.10.003. 
120. Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cycle-linked change s in 
GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and 
anxiety. Nat Neurosci . 2005;8(6):797-804. doi:10.1038/nn1469. 
121. Serra M, Mostallino MC, Talani G, et al. Social isolation-induced increase in alpha4  
and delta subunit gene expression is associated with a greater efficacy of ethanol 
on steroidogenesis and GABAA receptor function. Journal of Neurochemistry . 
2006;98(1):122-133. doi:10.1111/j.1471-4159.2006.[ZIP_CODE].x. 
122. Löfgren M, Johansson M, Str o mberg J, Meyerson B, B a ckstr o m TOR. The 
influence of social subordinate housing on the withdrawal effects from progesterone 
and estradiol in male rats. General and comparative endocrinology . 
2012;177(1):62-69. doi:10.1016/j.ygcen.2012.02.011. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 64 
 123. Serra M, Pi[INVESTIGATOR_898805], Littera M, et al. Social Isolation-Induced Decreases in Both the 
Abundance of Neuroactive Steroids and GABAA Receptor Function in Rat Brain. 
Journal of Neurochemistry . 2002;75(2):732-740. doi:10.1046/j.1471-
4159.2000.0750732.x. 
124. Lebron-Milad K, Graham BM, Milad MR. Low estradiol levels: a vulnerabil ity facto r 
for the development of posttraumatic stress disorder. Biological Psychiatry . 
2012;72(1):6-7. doi:10.1016/j.biopsych.2012.04.029. 
125. Glover EM, Jovanovic T, Mercer KB, et al. Estrogen levels are associated with 
extinction deficits in women with posttraumatic stress disorder. Biological 
Psychiatry . 2012;72(1):19-24. doi:10.1016/j.biopsych.2012.02.031. 
126. Bryant RA, Felmingham KL, Silove D, Creamer M, O'Donnell M, McFarlan e AC. 
The association between menstrual cycle and traumatic memories. Journal of 
Affective Disorders . 2011;131(1-3):398-401. doi:10.1016/j.jad.2010.10.049. 
127. Ossewaarde L, van Wingen GA, Rijpkema M, Bäckström T, Hermans EJ , 
Fernández G. Menstrual cycle-related changes in amygdala morphology are 
associated with changes in stress sensitivity. Hum Brain Mapp . 2011;34(5):1187-
1193. doi:10.1002/hbm.[ZIP_CODE]. 
128. Schiller CE, Schmidt PJ, Rubinow DR. Allopregnanolone as a mediator of af fective 
switching in reproductive mood disorders. Psychopharmacology . 
2014;231(17):3557-3567. doi:10.1007/s002 13-014- 3599 -x. 
129. Walf AA, Sumida K, Frye CA. Inhibiting 5α -reductase in the amygdala attenuates 
antianxiety and antidepressive behavior of naturally receptive and hormone-primed 
ovariectomized rats. Psychopharmacology . 2005;186(3):302-311. 
doi:10.1007/s [ADDRESS_1259716] immobility. Pharmacology, 
Biochemistry and Behavior . 2007;87(4):412-419. doi:10.1016/j.pbb.2007.05.017. 
131. Morrow AL, Biggio G, Serra M, et al. The role of neuroactive steroids in 
ethanol/stress interactions: proceedings of symposium VII at the Volterra 
conference on alcohol and stress, May 2008. Alcohol . 2009;43(7):521-530. 
doi:10.1016/j.alcohol.2009.04.002. 
132. Martinez PE, Rubinow DR, Nieman LK, et al. 5|[alpha]|-Reductase Inhibition 
Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and 
Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. 
Neuropsychopharmacology . 2016;41(4):10 93-1102. doi:10.1038/npp.2015.246. 
133. Frye CA, Rhodes ME, Petralia SM, Walf AA, Sumida K, Edinger KL. 3α -hydroxy- 5α-
pregnan- 20-one in the midbrain ventral tegmental area mediates social, sexual, and 
affective behaviors. Neuroscience . 2006;138(3):1007- 1014. 
doi:10.1016/j.neuroscience.2005.06.015. 
134. Frye CA, Walf AA, Rhodes ME, Harney JP. Progesterone enhances motor, 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 65 
 anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those 
deficient in type 1 5α -reductase. Brain Research . 2004;1004(1-2):116-124. 
doi:10.1016/j.brainres.2004.01.020. 
135. Smith SS, Gong QH, Hsu FC, Markowitz RS, ffrench-Mullen JM, Li X . GABA(A) 
receptor alpha4 subunit suppression prevents withdrawal properties of an 
endogenous steroid. Nature . 1998;392(6679):926- 930. doi:10.1038/[ZIP_CODE]. 
136. Smith SS, Gong QH, Li X, et al. Withdrawal from 3alpha- OH-5alpha-pregnan- 20-
One using a pseudopregnancy model alters the kinetics of hippocampal GABAA-
gated current and increases the GABAA receptor alpha4 subunit in association with 
increased anxiety. Journal of Neuroscience . 1998;18(14):5275- 5284.  
137. Mostallino MC, Sanna E, Concas A, Biggio G, Follesa P. Plasticity and funct ion of 
extrasynaptic GABA(A) receptors during pregnancy and after delivery. 
Psychoneuroendocrinology . 2009;[ADDRESS_1259717] 1:S74-S83. 
doi:10.1016/j.psyneuen.2009.06.013. 
138. Lovick TA, Griffiths JL, Dunn SMJ, Martin IL. Changes in GABA(A) receptor subunit 
expression in the midbrain during the oestrous cycle in Wistar rats. Neuroscience . 
2005;131(2):397-405. doi:10.1016/j.neuroscience.2004.11.010. 
139. Gordon JL, Girdler SS, Meltzer-Brody SE, et al. Ovarian Hormone Fluctuation, 
Neurosteroids, and HPA Axis Dysregulation in Perimenopausal Depression: A 
Novel Heuristic Model. American Journal of Psychiatry . 2015;172(3): 227-236. 
doi:10.1176/appi.ajp.2014.14070918. 
140. Sripada RK, Marx CE, King AP, Rampton JC, Ho SS. Allopregnanolone  elevations 
following pregnenolone administration are associated with enhanced activation of 
emotion regulation neurocircuits. Biological Psychiatry.  2013;73(11):1045- 1053.  
141. Husky M, Olié E, Guillaume SEB, Genty C, Swendsen J, Courtet P. Feasibili ty and 
validity of ecological momentary assessment in the investigation of suicide risk. 
Psychiatry Research . 2014;220(1-2):564-570. doi:10.1016/j.psychres.2014.08.019. 
142. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanol one 
levels and reactivity to mental stress in premenstrual dysphoric disorder. Biological 
Psychiatry . 2001;49(9):788-797. doi:10.1016/S0006-3223(00)[ZIP_CODE]- 1. 
143. Rosenthal MZ, Fang CM, Chapman AL. Ambulatory measurement of emotional 
dysfunction in borderline personality disorder. Current Opi[INVESTIGATOR_86832] . 
2015;3:75-79. doi:10.1016/j.copsyc.2015.02.008. 
144. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR.  Lack of 
Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome. 
The New England journal of medicine . 1991;324(17):1174-1179. 
doi:10.1056/NEJM199104253241705. 
145. Girdler SS, O'Briant C, Steege J, Grewen K, Light KC. A Compari son of the Effect 
of Estrogen with or without Progesterone on Mood and Physical Symptoms in 
Postmenopausal Women. Journal of Women's Health & Gender-Based Medicine . 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 66 
 1999;8(5):637-646. doi:10.1089/jwh.1.1999.8.637. 
146. Klatzkin RR, Morrow AL, Light KC, Pedersen CA, Girdler SS. Associations of  
histories of depression and PMDD diagnosis with allopregnanolone concentrations 
following the oral administration of micronized progesterone. 
Psychoneuroendocrinology . 2006;31(10):1208-1219. 
doi:10.1016/j.psyneuen.2006.09.002. 
147. Prinstein MJ. Introduction to the special section on suicide and nonsuicidal self-
injury: A review of unique challenges and important directions for self-inju ry 
science.  Journal of consulting and clinical psychology.  2008 Feb;76(1):1. 
148. Hilt LM, Nock MK, Lloyd-Richardson EE, Prinstein MJ. Longitudinal Study of  
Nonsuicidal Self-Injury Among Young Adolescents: Rates, Correlates, and 
Preliminary Test of an Interpersonal Model. The Journal of Early Adolescence . 
2008;28(3):455-469. doi:10.1177/0272431608316604. 
149. Bryan CJ, Rudd MD. Advances in the assessment of suicide risk. J Clin Psychol . 
2006;62(2):185-200. doi:10.1002/jclp.[ZIP_CODE]. 
150. Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom 
severity and steroid variation in women with premenstrual syndrome: study on 
serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 
alpha-hydroxy-5 alpha-pregnan- 20-one. The Journal of clinical endocrinology and 
metabolism . 2013;81(3):1076-1082. doi:10.1210/jcem.81.3.8772579. 
151. Kosnes L, Whelan R, O’Donovan A, McHugh LA. Implicit measurement of positive 
and negative future thinking as a predictor of depressive symptoms and 
hopelessness. Consciousness and Cognition . 2013;22(3):898-912. 
doi:10.1016/j.concog.2013.06.001. 
152. Wong J, Morrison AS, Heimberg RG, Goldin PR, Gross JJ. Implicit associations in  
social anxiety disorder: the effects of comorbid depression. Journal of Anxiety 
Disorders . 2014;28(6):537-546. doi:10.1016/j.janxdis.2014.05.008. 
153. Ray Li CS. Imaging Response Inhibition in a Stop-Signal Task: Neural Correlates 
Independent of Signal Monitoring and Post-Response Processing. Journal of 
Neuroscience . 2006;26(1):186-192. doi:10.1523/JNEUROSCI.3741-05.2006. 
154. Frewen PA, Dozois DJA, Joanisse MF, Neufeld RWJ. Selective attention to threat 
versus reward: meta-analysis and neural-network modeling of the dot-probe task. 
Clinical Psychology Review . 2008;28(2):307-337. doi:10.1016/j.cpr.2007.05.006. 
155. Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IJzendo orn 
MH. Threat-related attentional bias in anxious and nonanxious individuals: A meta-
analytic study. Psychological Bulletin . 2007;133(1):1-24. doi:10.1037/0033-
2909.133.1.1. 
156. Price RB, Allen KB, Silk JS, Ladouceur CD. Vigilance in the Laboratory P redicts 
Avoidance in the Real World: A Dimensional Analysis of Neural, Behavioral, and 
Ecological Momentary Data in Anxious Youth. Developmental Cognitive 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 67 
 Neuroscience. In press. 
157. Heatherton TF, Polivy J. Development and validation of a scale for measuring  state 
self-esteem.  Journal of personality and social psychology . 1991;60(6):895. 
158. Whiteside S, Lynam D. The Five Factor Model and impulsivity: using a structural 
model of personality to understand impulsivity. Personality and Individual 
Differences . 2001;30(4):669-689. doi:10.1016/S0191-8869(00)[ZIP_CODE]- 7. 
159. Spi[INVESTIGATOR_33594], Sydeman SJ, Owen AE, Marsh BJ. Measuring anxiety and anger 
with the State-Trait Anxiety Inventory (STAI) and the State-Trait  Anger Expression 
Inventory (STAXI). 1999. 
160. Nock MK, Holmberg EB, Photos VI, Michel BD. Self-Injurious Thoughts and 
Behaviors Interview: Development, Reliability, and Validity in an Adolescent 
Sample . Psychological Assessment. 2007;19:309- 317. 
161. Cole JC, Rabin AS, Smith TL, Kaufman AS. Development and Validation of a  
Rasch-Derived CES-D Short Form. Psychological Assessment. 2004;16(4): 360-
372. 
162. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: The  
Hopelessness Scale.  Journal of consulting and clinical psychology.  1974; 
42(6):861. 
163. Pi[INVESTIGATOR_5544], Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for 
measuring emotional distress from the Patient-Reported Outcomes Measurement 
Information System (PROMIS®): depression, anxiety, and anger. Assessment . 
2011;18(3):263-283. doi:10.1177/1073191111411667. 
164. Eynan R, Bergmans Y, Antony J, et al. The effects of suicide ideation assessments 
on urges to self-harm and suicide. Crisis . In Press. 
165. Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and 
Event Occurrence . Oxford university press; 2003. 
166. Davis LL, Broome ME, Cox RP. Maximizing Retention in Community ‐based Clinical 
Trials. Journal of Nursing Scholarship . 2002;34(1):47-53. 
167. Paykel ES, Myers JK, Lindenthal JJ, Tanner J. Suicidal feelings in the general 
population: a prevalence study. The British journal of psychiatry . 1974;124:460- 469. 
168. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: The Scale for 
Suicide Ideation.  Journal of consulting and clinical psychology. 1979;47(2):343- 352. 
169. Kuhl H. Pharmacology of estrogens and progestogens: influence of diff erent routes 
of administration. Climacteric . 2005;[ADDRESS_1259718] 1(s1):3-63. 
doi:10.1080/13697130500148875. 
170. De Leo V, Lanzetta D, Morgante G, De Palma P, D'Antona D. Inhibition of ovulatio n 
with transdermal estradiol and oral progestogens in perimenopausal women. 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 68 
 Contraception . 1997;55(4):239-243. doi:10.1016/S0010-7824(97)[ZIP_CODE]- 1. 
171. Girdler SS, Hinderliter AL, Wells EC, Sherwood A, Grewen KM, Light KC.  
Transdermal versus oral estrogen therapy in postmenopausal smokers: 
hemodynamic and endothelial effects. Obstetrics & Gynecology . 2004;103(1):169-
180. doi:10.1097/01.AOG.[PHONE_18661].[ZIP_CODE].0b. 
172. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen  plus 
progestin in healthy postmenopausal women: principal results From the Women's 
Health Initiative randomized controlled trial. JAMA . 2002;288(3):321- 333. 
173. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine 
estrogen in women without a uterus. Archives of internal medicine . 
2006;166(7):772-780. doi:10.1001/archinte.166.7.772. 
174. Reis dos CMRF, de Melo NR, Meirelles ES, Vezozzo DPA, Halpern A. Body 
composition, visceral fat distribution and fat oxidation in postmenopausal women 
using oral or transdermal oestrogen. Maturitas . 2003;46(1):59- 68. 
175. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for 
estrogen replacement therapy. American journal of obstetrics and gynecology . 
1995;173(3 Pt 2):998-1004. 
176. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. 
Comparison of transdermal to oral estradiol administration on hormonal and hepatic 
parameters in women with premature ovarian failure. Journal of Clinical 
Endocrinology & Metabolism . 1991;73(2):275-280. doi:10.1210/jcem- 73-2-275. 
177. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of tran sdermal 
estradiol. The New England journal of medicine . 1986;314(25):1615-1620. 
doi:10.1056/NEJM198606193142505. 
178. Rice VC, Richard-Davis G, Saleh AA, et al. Fibrinolytic parameters in women 
undergoing ovulation induction. American journal of obstetrics and gynecology . 
1993;169(6):1549- 1553.  
179. Saleh AA, Ginsburg KA, Duchon TA, et al. Hormonal contraception an d platelet 
function. Thrombosis research . 1995;78(4):363-367. 
180. Sifton DW. Physicians' desk reference. 2002. 
181. Scarabin P-Y, Oger E, Simon T, Plu-Bureau GEV. Estrogen plus progestin an d risk 
of venous thrombosis. JAMA . 2005;293(11):1322; authorreply1322-
authorreply1323. doi:10.1001/jama.293.11.1322- a. 
182. Jick H, Derby [CONTACT_29474], Myers MW, Vasilakis C, Newton KM. Risk of hospi[INVESTIGATOR_898806]. Lancet . 1996;348(9033):981-983. doi:10.1016/S0140-6736(96)[ZIP_CODE]-
0. 
183. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of ven ous 
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 69 
 thromboembolism risk in users of hormone replacement therapy. Lancet . 
1996;348(9033):1027. doi:10.1016/S0140-6736(96)[ZIP_CODE]- 3. 
184. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous 
hormones and risk of pulmonary embolism in women. Lancet . 1996;348(9033):983-
987. doi:10.1016/S0140-6736(96)[ZIP_CODE]- 4. 
185. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy  
over? Deconstructing the Women's Health Initiative study: a critical evaluation o f 
the evidence. Annals of the [LOCATION_001] Academy of Sciences . 2005;1052(1):43-56. 
doi:10.1196/annals.1347.004. 
186. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in  
postmenopausal women: July 2008 position statement of The North American 
Menopause Society. Menopause . 2015;15(4 Pt 1):584-602. 
doi:10.1097/gme.0b013e31817b076a. 
187. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy : an 
Endocrine Society scientific statement. The Journal of clinical endocrinology and 
metabolism . 2010;95([ADDRESS_1259719] 1):s1-s66. doi:10.1210/jc.2009-2509. 
188. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. 
Progesterone metabolite allopregnanolone in women with premenstrual syndrome. 
Obstetrics & Gynecology . 1997;90(5):709-714. doi:10.1016/S0029-7844(97)[ZIP_CODE]-
1. 
189. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. 
Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine 
estrogens on coronary artery atherosclerosis. Arteriosclerosis, thrombosis, and 
vascular biology . 1997;17(1):217-221. 
190. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the 
General Population. Applied Psychological Measurement . 1977;1(3):385-401. 
doi:10.1177/014662167700100306. 
 
 
 
 
 
  
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach Version 1 
Protocol [ IRB # 16-2078]  October 2, 2016 
  
Based on NIDCR Clinical Trial (Interventional) Protocol Template v4.0 - 201401 03 70 
 APPENDIX 
 
Version Date Significant Revisions  
   
   
 